Nutra Pharma (NPHC) 10-K 8 Sep 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Sep. 08, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	NUTRA PHARMA CORP
Entity Central Index Key	0001119643
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well Known Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 5,045,180
Entity Common Stock, Shares Outstanding		7,267,619,714
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash
Accounts receivable	37,080	32,479
Other receivable	3,000
Inventory, current portion	5,271	8,177
Prepaid expenses and other current assets	10,000	17,150
Total current assets	55,351	57,806
Inventory, less current portion	78,880	52,183
Property and equipment, net	14,742	6,763
Operating lease right-of-use assets	144,010	207,530
Security deposit	8,803	15,550
Total assets	301,786	339,832
Current liabilities:
Accounts payable	599,428	583,226
Accrued expenses	780,432	612,547
Accrued payroll due to officers	1,429,693	1,249,393
Accrued interest to related parties	179,522	159,555
Due to officer	200,837	122,812
Derivative liabilities	3,567,176	835,868
Other debt, net of discount, current portion	4,631,921	7,352,954
SBA notes payable, current portion	10,725
Operating lease obligations, current portion	82,873	73,278
Total current liabilities	11,482,607	10,989,633
Convertible note, less current portion	48,477	907,912
SBA notes payable, less current portion	204,070
Operating lease obligations, less current portion	60,447	143,322
Total liabilities	11,795,601	12,040,867
Commitments and Contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value, 20,000,000 shares authorized: 3,000,000 Series A Preferred shares issued and outstanding at December 31, 2020 and 2019	3,000	3,000
Common stock, $0.001 par value, 8,000,000,000 shares authorized: 6,955,197,214 and 5,876,746,111 shares issued and outstanding at December 31, 2020 and 2019	6,955,197	5,876,746
Additional paid-in capital	50,181,456	50,283,503
Accumulated deficit	(68,633,468)	(67,864,284)
Total stockholders' deficit	(11,493,815)	(11,701,035)
Total liabilities and stockholders' deficit	$ 301,786	$ 339,832

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	8,000,000,000	8,000,000,000
Common stock, shares issued	6,955,197,214	5,876,746,111
Common stock, shares outstanding	6,955,197,214	5,876,746,111
Series A Preferred Stock [Member]
Preferred stock, shares issued	3,000,000	3,000,000
Preferred stock, shares outstanding	3,000,000	3,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net sales	$ 51,897	$ 104,393
Cost of sales	(15,678)	(45,730)
Change in reserve for supplier advances for purchases	(21,303)	(23,948)
Gross profit	14,916	34,715
Operating expenses:
Selling, general and administrative - including stock based compensation of $8,500 and $71,500 for the years ended December 31, 2020 and 2019, respectively	1,101,363	1,202,819
Bad debt (recovery) expense - including related party of ($161,500) and $59,000 for the years ended December 31, 2020 and 2019, respectively	(161,500)	61,789
Total operating expenses	939,863	1,264,608
Loss from operations	(924,947)	(1,229,893)
Other income (expenses)
Other income	5,000
Interest expense	(316,207)	(244,278)
Interest expense to related parties	(19,967)	(17,747)
Change in fair value of convertible notes and derivatives	(1,012,556)	(5,184,445)
Stock issued for loan modification	(87,800)	(7,700)
Gain on settlement of debt and accrued expense, net	1,587,293	92,621
Total other income (expenses)	155,763	(5,361,549)
Loss before income taxes	(769,184)	(6,591,442)
Provision for income taxes
Net loss	$ (769,184)	$ (6,591,442)
Net loss per share - basic and diluted	$ 0	$ 0
Weighted average number of shares outstanding during the year - basic and diluted	6,607,482,758	4,710,306,385

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Stock based compensation	$ 8,500	$ 71,500
Related party bad debt	$ 161,500	$ 59,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 3,000	$ 4,046,746	$ 51,286,503	$ (61,272,842)	$ (5,936,593)
Balance, shares at Dec. 31, 2018	3,000,000	4,046,746,110
Issuance of common stock in exchange for services to consultants		$ 135,000	(105,000)		30,000
Issuance of common stock in exchange for services to consultants, shares		135,000,000
Common stock issued for debt modification and penalty		$ 22,000	(14,300)		7,700
Common stock issued for debt modification and penalty, shares		22,000,000
Common stock issued for conversion of debt		$ 750,000	(475,000)		275,000
Common stock issued for conversion of debt, shares		750,000,000
Common stock issued for settlement of accrued expense and debt		$ 881,000	(394,600)		486,400
Common stock issued for settlement of accrued expense and debt, shares		881,000,000
Common stock issued with Debt-Debt discount		$ 42,000	(29,617)		12,383
Common stock issued with Debt-Debt discount, shares		42,000,001
Warrants issued with Debt-Debt discount			15,517		15,517
Net loss				(6,591,442)	(6,591,442)
Balance at Dec. 31, 2019	$ 3,000	$ 5,876,746	50,283,503	(67,864,284)	(11,701,035)
Balance, shares at Dec. 31, 2019	3,000,000	5,876,746,111
Common stock issued for debt modification and penalty		$ 138,500	(50,700)		87,800
Common stock issued for debt modification and penalty, shares		138,500,000
Common stock issued for conversion of debt		$ 814,951	(13,847)		801,104
Common stock issued for conversion of debt, shares		814,951,103
Common stock issued for settlement of accrued expense and debt		$ 125,000	(37,500)		87,500
Common stock issued for settlement of accrued expense and debt, shares		125,000,000
Net loss				(769,184)	(769,184)
Balance at Dec. 31, 2020	$ 3,000	$ 6,955,197	$ 50,181,456	$ (68,633,468)	$ (11,493,815)
Balance, shares at Dec. 31, 2020	3,000,000	6,955,197,214

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (769,184)	$ (6,591,442)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in reserve for supplier advances for purchases	21,303	23,948
Bad debt expense		61,789
Bad debt recovery - related party	(161,500)
Accrued interest expense for amount due to officer	7,675	6,330
Gain (loss) on settlement of debt and accrued expense	(1,587,293)	(92,621)
Depreciation	3,831	3,737
Stock-based compensation	8,500	71,500
Stock-based loan modification expense	87,800	7,700
Change in fair value of convertible notes and derivatives	1,012,556	5,184,445
Amortization of loan discount	130,485	100,810
Amortization of operating lease right-of-use assets	63,520	73,645
Changes in operating assets and liabilities:
Increase in accounts receivable	(4,601)	(18,203)
Increase in notes receivable	(3,000)
Increase in inventory	(23,791)	(25,058)
Increase in prepaid expenses and other current assets	(15,906)	(19,598)
Increase in accounts payable	10,297	107,817
Increase in accrued expenses	214,235	209,970
Increase in accrued payroll due to officers	180,300	198,400
Increase in accrued interest to related parties	19,967	17,747
Decrease in operating lease obligations	(73,280)	(64,575)
Net cash used in operating activities	(878,086)	(743,659)
Cash flows from investing activities:
Acquisition of equipment	(5,905)
Net cash used in investing activities:	(5,905)
Cash flows from financing activities:
Loans from officer	254,000	5,000
Repayment of officer loans	(22,150)	(134,015)
Repayments of notes payable-related party	(14,400)
Proceeds from convertible notes	527,983	782,374
Repayment of convertible notes	(5,782)	(13,500)
Advances from an unrelated third party	50,000	175,000
Repayments of other notes payable	(120,455)	(71,200)
Proceeds from SBA notes payable	214,795
Net cash provided by financing activities	883,991	743,659
Net increase in cash
Cash - beginning of period
Cash - end of period
Supplemental Cash Flow Information:
Cash paid for interest	1,049	661
Cash paid for income taxes
Non Cash Financing and Investing:
Stock issued in settlement of notes, accounts payable, and accrued expenses	87,500	486,400
Shares issued for conversion of debt	801,104	275,000
Common stock issued with Debt-Debt discount		12,383
Warrants issued with Debt-Debt discount	105,000	15,517
Purchase of equipment included in accounts payable	5,905
Right-of-use asset due to adoption of ASC 842		281,175
Operating lease liabilities due to adoption of ASC 842		281,175
Reclassification of accrued interest to debt	$ 30,850	$ 66,460

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $68,633,468 at December 31, 2020. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $11,427,256 and a stockholders’ deficit of $11,493,815 at December 31, 2020. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $64,895. We used the proceeds primarily for payroll costs. We expect forgiveness of this loan under the current terms of requirement by the SBA. During April and June 2020, we obtained the loan in the amount of $150,000 from the SBA under its Economic Injury Disaster Loan assistance program. We used the proceeds primarily for rent, payroll, utilities, accounting and legal expenses (See Note 6). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. During the year ended December 31, 2019, $2,789 of accounts receivable were written off and recorded as bad debt expense. No allowance for doubtful account is deemed to be required at December 31, 2020 and 2019. Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2020 and 2019, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $21,303 and $23,948, respectively. At December 31, 2020 and 2019, the total valuation allowance for prepaid venom was $246,162 and $224,859, respectively. Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2020, there was one customer that accounted for 37% of the total revenues. For the year ended December 31, 2019, there were two customers that accounted for 55% and 12% of the total revenues. As of December 31, 2020 and 2019, 100% of the accounts receivable balance are reserves due from two payment processors. Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” (Topic 842), as amended (“ASC Topic 842”). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC Topic 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC Topic 842), therefore there was no change in accounting treatment required. The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC 815, Derivatives and Hedging Embedded Derivatives Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. Income Taxes We compute income taxes in accordance with FASB ASC Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2020 and 2019, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share 31-Dec-20 31-Dec-19 Options and warrants 202,775,000 52,500,000 Convertible notes payable at fair value 1,515,706,865 11,672,780,512 Convertible notes payable 2,814,694,508 1,624,914,267 Total 4,533,176,373 13,350,194,779 Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. ASU 2021-04 will be effective for fiscal years beginning after December 15, 2021 and interim periods within those fiscal years. Early adoption is permitted. This ASU will be applied prospectively to modifications or exchanges occurring on or after the effective date of the ASU. The Company is currently evaluating the impact this new guidance will have on its condensed consolidated financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at December 31, 2020 and 2019 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at December 31, 2020 and December 31, 2019: Fair Value Measurements at December 31, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 189,543 $ - $ - $ 189,543 Derivative liabilities $ 3,377,633 $ - $ 3,377,633 $ - Convertible notes at fair value $ 1,832,439 $ - $ - $ 1,832,439 Fair Value Measurements at December 31, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,411 $ - $ - $ 1,411 Derivative liabilities $ 834,457 $ - $ 834,457 $ - Convertible notes at fair value $ 5,814,047 $ - $ - $ 5,814,047 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2020 and 2019: Description 2020 2019 Beginning balance $ 1,411 $ 1,468 Purchases, issuances, and settlements 143,369 - Total loss (gain) included in earnings (1) 44,763 (57 ) Ending balance $ 189,543 $ 1,411 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 0.10% to 1.59% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 276% to 348% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at December 31, 2020 and 2019, respectively. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2020 and 2019: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2020 $ 766,101 8%-10% 20%-24% N/A $0.00050-$0.00064 50%-60% 3 to 25 Days 2019 $ 1,244,204 8%-10% 20%-24% N/A $0.00010-$0.000293 50%-60% 3 to 25 Days Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2020 and 2019: Description 2020 2019 Beginning balance $ 5,814,047 $ 1,156,341 Purchases and issuances 25,981 688,274 Day one loss on value of hybrid instrument (1) 318,174 926,109 Loss (gain) from change in fair value (1) (1,931,927 ) 3,423,935 Gain on settlement (1,609,294 ) - Debt discount 22,344 (22,344 ) Settlement through issuance of common stock - (83,268 ) Repayments in cash (5,782 ) - Conversion to common stock (801,104 ) (275,000 ) Ending balance $ 1,832,439 $ 5,814,047 (1) The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories	3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2020 and 2019, inventories were as follows: December 31, 2020 December 31, 2019 Raw Materials $ 78,880 $ 52,183 Finished Goods 5,271 8,177 Total Inventories 84,151 60,360 Less: Long-term inventory (78,880 ) (52,183 ) Current portion $ 5,271 $ 8,177

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at December 31, 2020 and 2019: December 31, December 31, Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 65,521 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 227,843 216,033 Less: Accumulated depreciation (213,101 ) (209,270 ) Property and equipment, net $ 14,742 $ 6,763 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2020, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2020 and 2019 was $3,831 and $3,737, respectively.

Due to_from Officer

Due to/from Officer	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Due to/from Officer	5. DUE TO/FROM OFFICER At December 31, 2020, the balance due to our President and CEO, Rik Deitsch, was $200,837, which is an unsecured demand loan that bears interest at 4%. During the year ended December 31, 2020, we advanced $22,150 to and collected $254,000 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $7,675 and is included in the due to officer account. For the year ended December 31, 2020, we recorded a bad debt recovery of $161,500. The Company has fully reserved receivables from companies owned by the Company’s CEO. The reserve was $402,970 as of December 31, 2020, which represents a full valuation allowance for amounts owed by these Companies. At December 31, 2019, the balance due to our President and CEO, Rik Deitsch, was $122,812, which is an unsecured demand loan that bears interest at 4%. During the year ended December 31, 2019, we advanced $134,015 to and collected $5,000 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $6,330 and is included in the due to officer account. For the year ended December 31, 2019, we recorded a bad debt expense of $59,000. The Company has fully reserved receivables from companies owned by the Company’s CEO. The reserve was $564,470 as of December 31, 2019, which represents a full valuation allowance for amounts owed by these Companies.

Debts

Debts	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debts	6. DEBTS Debts consist of the following at December 31, 2020 and 2019: December 31, 2020 December 31, 2019 Note payable– Related Party (1) $ - $ 14,400 Notes payable – Unrelated third parties (Net of discount of $1,500 and $8,921, respectively) (2) 1,346,057 1,385,163 Convertible notes payable – Unrelated third parties (Net of discount of $101,448 and $17,370, respectively) (3) 1,276,902 872,256 Convertible notes payable, at fair value (Net of discount of $0 and $22,344, respectively) (4) 1,832,439 5,814,047 Other advances from an unrelated third party (5) 225,000 175,000 SBA notes payable(6) 214,795 - Ending balances 4,895,193 8,260,866 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (48,477 ) (907,912 ) Less: Long-term portion- SBA notes payable (204,070 ) - Current portion $ 4,642,646 $ 7,352,954 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At December 31, 2020 and 2019, we owed this director accrued interest of $179,522 and $159,555. The interest expense for the years ended December 31, 2020 and 2019 was $19,967 and $17,747. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. The Note of $14,400 was paid in full in cash during June 2020. In addition, we issued 5,000,000 shares due to the default on repayment of the note. The shares were valued at fair value of $3,000(See Note 7). At December 31, 2020 and 2019, the principal balance of the loan is $0 and $14,400, respectively. (2) At December 31, 2020 and 2019, the balance of $1,346,057 and $1,385,163 net of discount of $1,500 and $8,921, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The Notes carry interest at 12% annually and were originally due on the date that was six-months from the execution and funding of the note. At December 31, 2018, we owed principal balance of $192,974, and accrued interest of $40,033. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020. During the first quarter of 2020, the settlement was amended to $88,500. We recorded a gain on settlement of debt in other income for $15,500 and $18,841 during the years ended December 31, 2020 and 2019, respectively. The Company repaid $13,500 and $75,000 during the years ended December 31, 2019 and 2020 to pay the settlement balance of $88,500 in full. At December 31, 2020 and 2019, we owed principal balance of $91,156 and 160,633, respectively, and accrued interest of $40,917 and $50,971, respectively. The remaining principal balance of $91,156 and accrued interest of $40,917 is being disputed in court and negotiation for settlement. (See Note 13). ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. We signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge, and it is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2020 and 2019, the accrued interest is $4,769 and $3,755. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At December 31, 2020 and 2019, the outstanding principal balance is $50,000 and accrued interest is $62,167 and $49,967. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2020 and 2019, the outstanding principal balance is $50,000 and accrued interest is $55,367 and $43,166. ● A promissory note originally issued to an unrelated third party in August 2016 was restated in the amount of $282,983 bearing monthly interest at a rate of 2.0% and was due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for this debt discount was fully amortized during the years ended December 31, 2019 and 2018 for $3,616 and $329, respectively. During September 2019, the note of $282,983 plus accrued interest amended in December 2018 was restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. During September 2020, we issued a total of 10,000,000 restricted shares due to the default on repayments. The shares were valued at fair value of $6,000 (See Note 7).The common stock was valued at $5,895(See Note 7) and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount for the years ended December 31, 2020 and 2019 was $4,421 and $1,474 and debt discount at December 31, 2020 and 2019 is $0 and $4,421. The Note is in default and negotiation of settlement. At December 31, 2020 and 2019, the principal balance is $333,543, and the accrued interest is $106,511 and $25,127, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At December 31, 2020 and 2019, the principal balance outstanding is $15,000 and the accrued interest is $1,371. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2020 and 2019, the accrued interest is $51,667 and $39,466, respectively. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2020 and 2019, the accrued interest is $4,483 and $3,212, respectively. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. The Company repaid a total of $34,976, $42,698, and $44,478 during 2018, 2019 and 2020, respectively. At December 31, 2020 and 2019, the principal balance is $48,250 and $92,728, respectively. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2020 and 2019, the principal balance of the note is $50,000. ● During September 2018 and 2019, a promissory note originally issued to an unrelated third party in September 2017 was amended in the amount of $36,000 including original issuance discount of $6,000 each due in September 2019 and 2020. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Debt discounts have been fully amortized during 2019 for $7,500 for the restated Notes in September 2018 and 2019. Repayments of $7,000, $5,000, and $6,500 have been made during 2018, 2019, and 2020, respectively. The Note is under personal guarantee by Mr. Deitsch. At December 31, 2020 and 2019, the principal balance of the note is $29,500 and $30,000, net of debt discount of $1,500 and $4,500, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. ● During November 2018, a promissory note originally issued to an unrelated third party in October 2017 was restated in the amount of $60,000 including original issuance discount of $10,000 due May 2019. During July 2019, payment of original issuance discount of $10,000 was made. During September 2019, we issued additional 10,000,000 restricted shares due to the late payment of the original issuance discount of $10,000. The shares were valued at fair value of $4,000. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Debt discount and original issuance discount have been fully amortized during 2019 for $8,254. As of December 31, 2019, the amount due is $60,000. During January 2020, the Note of $60,000 and the Note of $76,076 (See Note 6(3)) plus accrued interest of $12,149 were combined and restated at a rate of 2.0% monthly due July 2020. During July 2020, the restated principal balance of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance of $166,926 carries interest at a rate of 2.0% monthly and was due January 2021. At December 31, 2020, the restated principal balance and accrued interest was $166,926 and $18,917. The principal balance plus accrued interest was further restated in February 2021 and was due in August 2021(See Note 13). The note is in default and in negotiation of settlement. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. During March 2020, $50,000 of the Note was settled for 125,000,000 shares with a fair value of $87,500. We recorded a loss on settlement in other expense for $37,500 (See Note 7). An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $32,200. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At December 31, 2020 and 2019, the principal balance of the loan is $84,000 and $120,000, respectively. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note is in default and in negotiation of settlement. The note was due in six months from the execution and funding of the note. At December 31, 2020 and 2019, the principal balance of the note is $18,000 and the accrued interest is $2,000. (3) At December 31, 2020 and 2019, the balance of $1,276,902 and $872,256 net of discount of $101,448 and $17,370, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During August 2018, a promissory note originally issued to an unrelated third party in July 2016 was restated in the amount of $76,076 bearing monthly interest at a rate of 2.5% and was due February 2019. The debt discount from 2018 has been fully amortized with the remaining $950 amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At December 31, 2019, the convertible note payable and accrued interest was recorded at $76,076 and $12,150, respectively. During January 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated. The principal balance plus accrued interest was further restated in July 2020 and February 2021 and is due in August 2021. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option. The note was due in six months from the execution and funding of the note. The loan is in default and in negotiation of settlement. At December 31, 2020 and 2019, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The total discount of $255,655 and original issuance discount of $62,950 have been fully amortized during 2019 for $28,421. During February 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. In connection with the issuance and restatements of the notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. During August 2020, the convertible promissory notes of $38,500 was amended to add additional original issuance discount (OID) of $7,550 due February 2021. During October 2020, a convertible promissory note of $16,500 was amended to add additional OID of $1,650 due April 2021.The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0005. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $123,900 on December 31, 2020 (See Note 8). The debt discounts associated with the warrants in August was for $38,500. The debt discounts associated with the warrants in October was for $16,500. The debt discounts are amortized over the life of the notes. Month of Issuance Number of Warrants Fair Value of Warrants Recorded as Debt Discount Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 August, 2020 92,100,000 $ 38,500 August, 2021 October, 2020 36,300,000 $ 16,500 October, 2022 During May 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During November 2019, we issued a convertible promissory note to an unrelated third party for $137,500 with original issuance discount of $12,500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.000275. The Note is in default and negotiation of settlement. During December 2019, we issued a convertible promissory note to an unrelated third party for $22,000 with original issuance discount of $2,000. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The Note is in default and negotiation of settlement. During 2019, repayments of $13,500 were made in cash to three of the Notes. Six of the Notes for a total of $87,100 were repaid in stocks as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019(see Note 7). Amortization for the year ended December 31, 2019 was $55,222. At December 31, 2019, the principal balance of the notes, net of discount of $17,370 was $736,180. The remaining debt discount of $17,370 has been fully amortized during the fiscal year 2020. Two of the above mentioned convertible notes payable for a total of $19,500 were settled in full in March and April 2021(See Note 13). During the year ended December 31, 2020, we issued convertible notes payable of $555,600 with original issuance discount of $53,600. $287,400 of these notes were due in a year, and $268,200 of the Notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0002 to 0.0008 per share. During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700 (See Note 7). In addition, in connection with the issuance of two of the above mentioned convertible notes of $57,500 with original issuance discount of $7,500 due in one year, the Company granted the 71,875,000 warrants at an exercise price of $0.002 per share that expire one year from the date of issuance. The warrants are valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The debt discounts associated with the warrants and OID for $50,000 and $7,500, respectively, are amortized over the life of the notes. Amortization for the year ended December 31, 2020 was $83,720. The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $65,634 using the Black-Scholes method on December 31, 2020 (See Note 8). At the date of this report, $1,121,700 of the above mentioned convertible notes payable are in default and in negotiation of settlement. At December 31, 2020, the principal balance of the notes, net of discount of $101,448 is $1,276,902. (4) At December 31, 2020 and 2019, the balance of $1,832,439 and $5,814,047 net of discount of $0 and $22,344, respectively, consisted of the following convertible loans: ● The remaining balance of $20,000 of a Convertible Note of $120,000 originated in March 2016 is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At December 31, 2020 and 2019, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $69,433 and $56,373, respectively. ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note was due on May 4, 2018. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. We have accrued interest at default interest rate of 20% after the note’s maturity date. After prior conversions, during December 2019, the principal balance of $16,752 with accrued interest of $3,232 previously assigned and sold to a third party in February 2018 was settled as part of issuances of 800,000,000 shares of common stocks (See Note 7). At December 31, 2020 and 2019, the remaining principal of $12,629 plus accrued interest of $12,308 and $9,782, respectively, at fair value, was recorded at $49,875 and $62,253, respectively. The remaining principal balance of the Note is in default. All of the convertible notes discussed below are with a single unrelated third party. ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019 (See Note 7). The new note of $49,819 carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. The conversion discount was further decreased to fifty percent due to the default on the Note. During September 2018, the Noteholder made a conversion of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At December 31, 2019, the convertible note payable with principal balance of $38,301, at fair value, was recorded at $246,819. ● During February 2018, we issued a convertible debenture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At December 31, 2019, the convertible note payable with principal balance of $220,000, at fair value, was recorded at $1,412,175. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At December 31, 2019, the convertible note payable with principal balance of $71,500, at fair value, was recorded at $458,957. ● During March 2018, we issued a convertible debenture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in March 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At December 31, 2019, the convertible note payable with principal balance of $66,000, at fair value, was recorded at $417,576. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. ● During June 2018, the $60,000 Back-end Note was funded. The note carries interest at 8% and was due in March 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At December 31, 2019, the convertible note payable with principal balance of $66,000, at fair value, was recorded at $417,577. ● During May 2018, we issued a convertible debenture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in May 2019, unless previously converted into shares of restricted common stock. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At December 31, 2019, the convertible note payable with principal balance of $60,000, at fair value, was recorded at $369,372. ● During August 2018, we issued a convertible debenture in the amount of $31,500 to an unrelated third party. The note carries interest at 8% and was due in August 2019, unless previously converted into shares of restricted common stock. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At December 31, 2019, the convertible note payable with principal balance of $31,500, at fair value, was recorded at $183,565. All of the above convertible notes with principal balance of a total of $511,319 as of December 31, 2019, plus the additional principal increases due to the default terms, were settled in October 2020. During September 2020, the Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345 (See Note 7). During October 2020, the Note holder sold the remaining debt principal value as of October 22, 2020 of $509,301 and accrued interest of $234,417 for $250,000 to a non-related party. Based on the conversion methodology, the debt was valued at $1,859,294 prior to conversion, and the Company recorded a gain on settlement of $1,609,294, which is recorded within gain (loss) on settlement of debt, net, within the statement of operations. Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691 ● The new note of $250,000 carries interest at 8%. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. In connection with the issuance of the convertible note payable, we rec

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Deficit	7 . STOCKHOLDERS’ DEFICIT Authorized Shares On March 7, 2018, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 2,000,000,000 to 8,000,000,000. Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination to authorize the issuance of 20,000,000 shares of stock designated “preferred shares”, issuable from time to time in one or more series and authorize the Board of Directors to fix the number of shares constituting any such series, and to determine or alter the dividend rights, dividend rate, conversion rights, voting rights, right and terms of redemption (including sinking fund provisions), the redemption price or prices and the liquidation preference of any wholly unissued series of such preferred shares, and the number of shares constituting any such series. Effective October 30, 2017 the Board of Directors authorized the issuance of 3,000,000 shares of Series A Preferred Stock (“Series A Preferred”). Terms of the Series A Preferred include the following: 1. The Series A Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred is entitled to one thousand votes per share. 2. The Series A Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series A Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series A Preferred will have the same record and payment date and terms as the dividend payable on the common stock. 3. Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series A Preferred then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount in cash equal to $0.133 in cash per share before any distribution is made on any shares of the Company’s common stock. If upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the application of all amounts available for payments with respect to Series A Preferred would not result in payment in full of Series A Preferred, the holders shall share equally and ratably in any distribution of assets of the Company in proportion to the full liquidation preference to which each is entitled. 4. The Series A Preferred does not have any redemption rights. Common Stock Issued with Indebtedness In May 2019, in connection with amendment of two convertible notes payable, we issued a total of 6,000,001 shares of our common stock with a fair value of $1,800 (See Note 6). In June 2019, in connection with issuance of a convertible notes payable, we issued a total of 16,000,000 shares of our common stock with a fair value of $4,688 (See Note 6). In September 2019, in connection with amendment of a promissory notes payable, we issued 20,000,000 shares of our common stock with a fair value of $5,895 (See Note 6). Common Stock Issued for Conversion of Convertible Debt During May and June 2019, the Note holder made conversions of a total of 750,000,000 shares of stock for a fair value of $275,000 satisfying the principal balance of $100,000 of a Note originated in February 2019 in the amount of up to $1,000,000 (See Note 6). Number of Fair Value of Date shares converted Debt 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000 During January 2020 through February 2020, the Note holder made conversions of a total of 500,000,000 shares of our restricted common stock satisfying the principal balance of $175,000 of a Note originated in February 2019. Number of Fair Value of Date shares converted Debt 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes prior to the following conversions was $511,319. During September 2020, the Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345. Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691 During November 2020, the Note holder assigned $20,000 of the $75,900 convertible note restated in January 2019 to a third party. The third party subsequently received a total of 100,000,000 shares of our restricted common stock in satisfaction the $20,000 of the Note with a fair value of $140,000. Common Stock Issued for Settlement of Accounts Payable, Accrued expense and Debt During January 2019, in connection with the settlement of a default penalty of debt of $110,000 originated in December 2016, we issued a total of 81,000,000 shares of our restricted common stock with a fair value of $32,400 to the Note holder (See Note 6). We had an accrual of $32,400 to account for the cost of the shares at December 31, 2018. During December 2019, six convertible promissory Notes for a total of $87,100 (See Note 6(3)), one Note of $19,984 assigned from the convertible Note of $29,381 (See Note 6(4)), and the accrued consulting fees of $39,000, were settled with 800,000,000 shares of common stocks. The shares were valued at fair value of $454,000. We recorded a loss on settlement in other expense for $244,632. Common Stock Issued for Debt Modification and Penalty During May and June 2019, we issued a total of 3,500,000 restricted shares to three Note holders due to the default on repayment of the convertible notes. The shares were valued at fair value of $1,050. During July through September 2019, we issued a total of 18,500,000 restricted shares to five Note holders due to the default on repayment of the convertible notes. The shares were valued at fair value of $6,650. During January 2020, we issued a total of 75,000,000 shares to a Note holder due to the default on repayment of the promissory notes. The shares were valued at fair value of $45,000. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. During June 2020, we issued 5,000,000 shares due to the default on repayment of a related party Note of $14,400 amended in December 2018. The shares were valued at fair value of $3,000. During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700. During September 2020, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $333,543 plus accrued interest amended in September 2019. The shares were valued at fair value of $6,000. During October 2020, we issued a total of 1,500,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $84,000 amended in March 2020. The shares were valued at fair value of $900. Common Stock Issued for Services During June 2018, the Company signed an agreement with a consultant for investor relation services for twelve months. In connection with the agreement, 100,000,000 shares of the Company’s restricted common stocks were issued. The shares were valued at $0.0012 per share. The Company recorded an equity compensation charge of $50,000 during the year ended December 31, 2019. During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 shares of our restricted common stock were issued. The shares were valued at $24,000. During June 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 15,000,000 shares of our restricted common stock were issued. The shares were valued at $6,000. The Company recorded an equity compensation charge of $8,500 and $21,500 during the years ended December 31, 2020 and 2019.

Stock Warrants

Stock Warrants	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Warrants	8. STOCK WARRANTS Common Stock Warrants On March 31, 2017, in connection with the issuance of an $80,000 Note, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $0 and $539 using the Black-Scholes method on December 31, 2020 and 2019. The warrants expired on March 30, 2020. On March 3, 2016, in connection with the issuance of a convertible note, we granted five-year warrants to purchase an aggregate of 2,500,000 shares of our common stock at an exercise price of $0.03 per share. The warrants were valued at their fair value of $9 and $872 using the Black-Scholes method at December 31, 2020 and 2019. The warrants expired on March 3, 2021. On April 4, 2016, in connection with the issuance of convertible notes, we granted three-year warrants to purchase an aggregate of 4,000,000 shares of our common stock at an exercise price of $0.05 per share. The warrants expired on April 4, 2019. During April 2014, the Company issued a total of 100,000 warrants to purchase common stock at an exercise price of $0.025 per share in connection with issuance of a convertible note payable to Coventry. The warrants expired on April 9, 2019. The Company granted the following warrants at an exercise price of $0.001 per share in connection with issuances of three convertible notes payable of $70,000 in February 2019 and amendment of one convertible notes payable of $22,000 in December 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Month of Issuance Number of Warrants Fair Value of Month of February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 During August 2020, convertible promissory notes of $38,500 were amended with additional original issuance discount of $7,550 due February 2021. During October 2020, a convertible promissory note of $16,500 was amended with additional OID of $1,650 due April 2021. In connection with the issuance of these amended convertible notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $123,900 using the Black-Scholes method on December 31, 2020 (See Note 7). Fair Value of Month of Issuance Number of Warrants Warrants Month of Expiration August, 2020 92,100,000 $ 38,500 August, 2021 October, 2020 36,300,000 $ 16,500 October, 2022 The Company granted the 71,875,000 warrants at an exercise price of $0.002 per share that expire one year from the date of issuance in connection with the issuance of the two convertible notes of $57,500 with original issuance discount of $7,500 due in one year,. The warrants are valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The debt discounts associated with the warrants and OID for $50,000 and $7,500, respectively, are amortized over the life of the notes. The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $65,634 using the Black-Scholes method on December 31, 2020 (See Note 7). A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2020 and 2019: Number Of Weighted Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 154,000,000 0.001 Expired (114,100,000 ) 0.0027 Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued 200,275,000 0.0014 Expired (50,000,000 ) 0.0015 Balance December 31, 2020 202,775,000 $ 0.0017 The following table summarizes information about fixed-price warrants outstanding as of December 31, 2020 and 2019 : Exercise Price Weighted Average Number Outstanding Weighted Weighted 2020 $ 0.001-0.03 51,086,612 0.93 years $ 0.0017 2019 $ 0.001-0.03 10,187,671 0.62 years $ 0.0028 At December 31, 2020, the aggregate intrinsic value of all warrants outstanding and expected to vest was $25,680. The intrinsic value of warrant share is the difference between the fair value of our restricted common stock and the exercise price of such warrant share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money warrants had they exercised their warrants on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on $0.0012, the closing stock price of our restricted common stock on December 31, 2020. There were 128,400,000 in-the-money warrants at December 31, 2020.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	9. INCOME TAXES The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2020 and 2019, (computed by the following blended rate), are approximately as follows. 2020 2019 Tax Rate Reconciliation: Federal tax rate 21.00 % 21.00 % Add: State taxes 5.50 % 5.50 % Permanent difference -1.15 % -1.15 % Valuation allowance -25.35 % -25.35 % Tax rate - - December 31, 2020 2019 Computed “expected” tax expense (benefit) - Federal $ (161,529 ) (1,384,203 ) Computed “expected” tax expense (benefit) - State (33,421 ) (286,398 ) Permanent differences (145,667 ) 1,313,998 Change in valuation allowance 340,617 356,603 Provision for income taxes $ - $ - 2020 2019 Net deferred income tax assets: Reserve for prepaid inventory $ 23,573 $ 18,174 Accrued salary 362,356 316,659 Reserve(recovery) for receivables from officer (25,979 ) 14,954 Net operating loss carryforwards 9,729,342 9,398,889 Valuation allowance (10,089,292 ) (9,748,676 ) Net deferred income tax asset $ - $ - Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets. The valuation allowances increased by $340,617 and $356,603 for the years ended December 31, 2020 and 2019. As of December 31, 2020, the Company has net operating loss of approximately $38.4 million as of December 31, 2020, of which $3.0 million were incurred after December 31, 2017 that are available to offset future taxable income with no expiration date. The remaining approximately $35.4 million of net operating losses expire between 2024 and 2037. The Company’s 2017 through 2020 tax returns are subject to examination by the Internal Revenue Services and various state authorities.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses	10. ACCRUED EXPENSES Accrued expenses consisted of the following: December 31, 2020 2019 Accrued consulting fees $ 166,900 $ 161,550 Accrued settlement expenses 35,000 35,000 Accrued payroll taxes 215,581 167,906 Accrued interest 351,830 231,186 Accrued others 11,121 16,905 Total $ 780,432 $ 612,547

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	11. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: December 31, December 31, Supplier advances for future purchases $ 246,162 $ 224,859 Reserve for supplier advances (246,162 ) (224,859 ) Net supplier advances - - Prepaid professional fees 10,000 8,650 Deferred stock compensation - 8,500 Total $ 10,000 $ 17,150 We performed an evaluation of our inventory and related accounts at December 31, 2020 and 2019, and increased the reserve on supplier advances for future venom purchases by $21,303 and $23,948, respectively. At December 31, 2020 and 2019, the total valuation allowance for prepaid venom is $246,162 and $224,859, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into a three-year operating lease for monthly payments of approximately $3,200 which expired in February 2019. We continued the lease on a month-to-month basis until May 2020 when it was terminated. ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. December 31, December 31, 2020 2019 Lease cost Operating lease cost $ 89,021 $ 89,021 Short-term lease cost 18,698 45,026 Total lease cost $ 107,719 $ 134,047 Balance sheet information Operating ROU Assets $ 144,010 $ 207,530 Operating lease obligations, current portion 82,873 73,278 Operating lease obligations, non-current portion 60,447 143,322 Total operating lease obligations $ 143,320 $ 216,600 Weighted average remaining lease term (in years) – operating leases 1.67 2.67 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows, for the years ended December 31, 2020 and 2019: Cash paid for amounts included in the measurement of operating lease liabilities $ 98,780 $ 79,950 Future minimum payments under these lease agreements are as follows: December 31, Total 2021 91,379 2022 62,274 Total future lease payments $ 153,653 Less imputed interest 10,333 Total $ 143,320 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. As the services provided were in dispute, the shares and note payable have not been issued as of December 31, 2020. We have accrued the $142,500 in accrued expense and equity compensation. During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 shares of the Company’s restricted common stock were granted and the Company was to make monthly cash payments of $3,000. As of December 31, 2016, the Company recorded an equity compensation charge of $31,750, however, only 1,000,000 of the shares have been issued. As of December 31, 2020 and 2019, $19,150 has been recorded in accrued expense to account for the 1,500,000 shares of common stock that have not been issued. Litigation Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and ReceptoPharm to recover $315,000 allegedly owing to them under a settlement agreement reached in an involuntary bankruptcy action that was brought by the same individuals in 2012 and for payment of unpaid wages/breach of written debt confirms. On June 24, 2021, the parties entered into a confidential settlement agreement of the lawsuit. Nutra Pharma has fully performed under the settlement and considers the case fully resolved. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against the Company and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. Counsel for Get Credit Healthy, Inc. requested an early mediation conference in an attempt to resolve our dispute. We agreed to this request, and mediation took place on February 15, 2019. The lawsuit was settled on February 15, 2019 for $104,000 and amended for $88,500 in first quarter of 2020 with scheduled payments. The repayments were made in full as of November 2020 (See Note 6). CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note (contrary to the Get Credit Healthy lawsuit discussed above, we are certain that this individual is the majority owner of CSA 8411, LLC). Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At December 31, 2020, we owed principal balance of $91,156 and accrued interest of $40,917 (See Note 6) if the defenses and our new claims are deemed to be of no merit. Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021. At this time the Court has not ruled on the pending Motion. Nutra Pharma disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	13. SUBSEQUENT EVENTS Convertible Notes Payable Pursuant to the Note agreement in the amount up to $1,000,000 signed in February 2019, the proceeds in the amount of $392,573 have been funded as of December 31, 2020. Proceeds in the amount of $86,520 have been funded subsequent to December 31, 2020. During February through June 2021, the Note holder received a total of 240,350,000 shares of our restricted common stock in satisfaction the $120,175 of the Note with a fair value of $2,344,399. The remaining balance of $83,917 is due June 2023. Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 During the first quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $717,667 with original issuance discount of $93,609. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.0003 to $0.002 per share. The notes are due one year from the execution and funding of the notes. During the second quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $864,225 with original issuance discount of $112,725. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.0008 to $0.002 per share. The notes are due one year from the execution and funding of the notes. During July and August 2021, we issued convertible promissory notes to the unrelated third parties for a total of $415,150 with original issuance discount of $54,150. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.002 per share. The notes are due one year from the execution and funding of the notes. Restatement of Promissory Notes During July 2020, the restated Note of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance was $166,926 that carries interest at a rate of 2.0% monthly and was due January 2021. During February 2021, we issued 29,072,500 shares of common stock to satisfy the accrued interest of $23,258 with fair value of $343,056. The settlement of accrued interest resulted in a loss on settlement of debt in other income for $319,798. The principal balance of $166,926 was further restated. The restated balance is $183,619 with an original issuance discount of $16,693 and was due August 2021. The note is in default and negotiation of settlement. Settlement of Convertible Promissory Notes During March 2021, in connection with this settlement of the $6,000 of the Note of $11,000 originated in November 2018, we issued 11,000,000 shares of common stocks in satisfaction of $6,000 of the Note with a fair value of $104,500 and made a repayment of $5,000 in cash. The settlement resulted in a loss on settlement of debt in other expense for $98,500. During April 2021, in connection with this settlement of the remaining balance of $8,500 of the Note of $12,000 originated in December 2018, we issued 2,000,000 shares of common stocks in satisfaction of $4,000 of the Note with a fair value of $15,200 and made a repayment of $4,500 in cash. The settlement resulted in a loss on settlement of debt in other expense for $11,200. Common Stock Issued for Default Payments During January 2021, we issued a total of 25,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $166,926 amended in July 2020. The shares were valued at fair value of $107,500. Common Stock Issued for Consulting Service During June 2021, the Company signed an agreement with a consultant for services for six months for which the Company is to issue 30,000,000 shares of the Company’s restricted common stock. 5,000,000 of the shares were issued upon execution of the agreement and 5,000,000 shares will be issued every 30 days through November 2021. The compensation charge will be amortized over the term of the agreement. Convertible notes receivable On March 10, 2021, we purchased a convertible note from an unrelated third party for a total of $26,950 with original issuance discount of $2,450. The note is convertible into common shares for $0.01 per common share and mature on March 10, 2022. On May 20, 2021, we purchased a convertible note from an unrelated third party for a total of $145,200 with original issuance discount of $13,200. The note is convertible into common shares for $0.01 per common share and mature on May 20, 2022. On August 5, 2021, we purchased a convertible note from an unrelated third party for a total of $55,000 with original issuance discount of $5,000. The note is convertible into common shares for $0.01 per common share and mature on August 5, 2022.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Organization	Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ®
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Liquidity and Going Concern	Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $68,633,468 at December 31, 2020. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $11,427,256 and a stockholders’ deficit of $11,493,815 at December 31, 2020. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Impact of COVID-19 on our Operations	Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $64,895. We used the proceeds primarily for payroll costs. We expect forgiveness of this loan under the current terms of requirement by the SBA. During April and June 2020, we obtained the loan in the amount of $150,000 from the SBA under its Economic Injury Disaster Loan assistance program. We used the proceeds primarily for rent, payroll, utilities, accounting and legal expenses (See Note 6). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine.
Use of Estimates	Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue from Contracts with Customers	Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor.
Accounting for Shipping and Handling Costs	Accounting for Shipping and Handling Costs We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. During the year ended December 31, 2019, $2,789 of accounts receivable were written off and recorded as bad debt expense. No allowance for doubtful account is deemed to be required at December 31, 2020 and 2019.
Inventories	Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2020 and 2019, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $21,303 and $23,948, respectively. At December 31, 2020 and 2019, the total valuation allowance for prepaid venom was $246,162 and $224,859, respectively.
Financial Instruments and Concentration of Credit Risk	Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2020, there was one customer that accounted for 37% of the total revenues. For the year ended December 31, 2019, there were two customers that accounted for 55% and 12% of the total revenues. As of December 31, 2020 and 2019, 100% of the accounts receivable balance are reserves due from two payment processors.
Operating Lease Right-of-Use Asset and Liability	Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” (Topic 842), as amended (“ASC Topic 842”). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC Topic 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC Topic 842), therefore there was no change in accounting treatment required. The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate.
Derivative Financial Instruments	Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Convertible Debt	Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.
The Fair Value Measurement Option	The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging
Derivative Accounting for Convertible Debt and Options and Warrants	Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC 815, Derivatives and Hedging Embedded Derivatives
Property and Equipment	Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.
Long-Lived Assets	Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.
Income Taxes	Income Taxes We compute income taxes in accordance with FASB ASC Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2020 and 2019, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation
Net Loss Per Share	Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share 31-Dec-20 31-Dec-19 Options and warrants 202,775,000 52,500,000 Convertible notes payable at fair value 1,515,706,865 11,672,780,512 Convertible notes payable 2,814,694,508 1,624,914,267 Total 4,533,176,373 13,350,194,779
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. ASU 2021-04 will be effective for fiscal years beginning after December 15, 2021 and interim periods within those fiscal years. Early adoption is permitted. This ASU will be applied prospectively to modifications or exchanges occurring on or after the effective date of the ASU. The Company is currently evaluating the impact this new guidance will have on its condensed consolidated financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share	As of December 31, 2020 and 2019, the following items were not included in the calculation of dilutive loss per share as the effect is anti-dilutive: 31-Dec-20 31-Dec-19 Options and warrants 202,775,000 52,500,000 Convertible notes payable at fair value 1,515,706,865 11,672,780,512 Convertible notes payable 2,814,694,508 1,624,914,267 Total 4,533,176,373 13,350,194,779

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Financial Instruments Measured at Fair Value	The following table summarizes our financial instruments measured at fair value at December 31, 2020 and December 31, 2019: Fair Value Measurements at December 31, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 189,543 $ - $ - $ 189,543 Derivative liabilities $ 3,377,633 $ - $ 3,377,633 $ - Convertible notes at fair value $ 1,832,439 $ - $ - $ 1,832,439 Fair Value Measurements at December 31, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,411 $ - $ - $ 1,411 Derivative liabilities $ 834,457 $ - $ 834,457 $ - Convertible notes at fair value $ 5,814,047 $ - $ - $ 5,814,047
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs	The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2020 and 2019: Description 2020 2019 Beginning balance $ 1,411 $ 1,468 Purchases, issuances, and settlements 143,369 - Total loss (gain) included in earnings (1) 44,763 (57 ) Ending balance $ 189,543 $ 1,411 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.
Summary of Assumptions and the Significant Terms	The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2020 and 2019: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2020 $ 766,101 8%-10% 20%-24% N/A $0.00050-$0.00064 50%-60% 3 to 25 Days 2019 $ 1,244,204 8%-10% 20%-24% N/A $0.00010-$0.000293 50%-60% 3 to 25 Days
Convertible Notes Payable [Member]
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs	The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2020 and 2019: Description 2020 2019 Beginning balance $ 5,814,047 $ 1,156,341 Purchases and issuances 25,981 688,274 Day one loss on value of hybrid instrument (1) 318,174 926,109 Loss (gain) from change in fair value (1) (1,931,927 ) 3,423,935 Gain on settlement (1,609,294 ) - Debt discount 22,344 (22,344 ) Settlement through issuance of common stock - (83,268 ) Repayments in cash (5,782 ) - Conversion to common stock (801,104 ) (275,000 ) Ending balance $ 1,832,439 $ 5,814,047 (1) The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2020 and 2019, inventories were as follows: December 31, 2020 December 31, 2019 Raw Materials $ 78,880 $ 52,183 Finished Goods 5,271 8,177 Total Inventories 84,151 60,360 Less: Long-term inventory (78,880 ) (52,183 ) Current portion $ 5,271 $ 8,177

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following at December 31, 2020 and 2019: December 31, December 31, Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 65,521 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 227,843 216,033 Less: Accumulated depreciation (213,101 ) (209,270 ) Property and equipment, net $ 14,742 $ 6,763

Debts (Tables)

Debts (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Debt	Debts consist of the following at December 31, 2020 and 2019: December 31, 2020 December 31, 2019 Note payable– Related Party (1) $ - $ 14,400 Notes payable – Unrelated third parties (Net of discount of $1,500 and $8,921, respectively) (2) 1,346,057 1,385,163 Convertible notes payable – Unrelated third parties (Net of discount of $101,448 and $17,370, respectively) (3) 1,276,902 872,256 Convertible notes payable, at fair value (Net of discount of $0 and $22,344, respectively) (4) 1,832,439 5,814,047 Other advances from an unrelated third party (5) 225,000 175,000 SBA notes payable(6) 214,795 - Ending balances 4,895,193 8,260,866 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (48,477 ) (907,912 ) Less: Long-term portion- SBA notes payable (204,070 ) - Current portion $ 4,642,646 $ 7,352,954 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At December 31, 2020 and 2019, we owed this director accrued interest of $179,522 and $159,555. The interest expense for the years ended December 31, 2020 and 2019 was $19,967 and $17,747. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. The Note of $14,400 was paid in full in cash during June 2020. In addition, we issued 5,000,000 shares due to the default on repayment of the note. The shares were valued at fair value of $3,000(See Note 7). At December 31, 2020 and 2019, the principal balance of the loan is $0 and $14,400, respectively. (2) At December 31, 2020 and 2019, the balance of $1,346,057 and $1,385,163 net of discount of $1,500 and $8,921, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The Notes carry interest at 12% annually and were originally due on the date that was six-months from the execution and funding of the note. At December 31, 2018, we owed principal balance of $192,974, and accrued interest of $40,033. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020. During the first quarter of 2020, the settlement was amended to $88,500. We recorded a gain on settlement of debt in other income for $15,500 and $18,841 during the years ended December 31, 2020 and 2019, respectively. The Company repaid $13,500 and $75,000 during the years ended December 31, 2019 and 2020 to pay the settlement balance of $88,500 in full. At December 31, 2020 and 2019, we owed principal balance of $91,156 and 160,633, respectively, and accrued interest of $40,917 and $50,971, respectively. The remaining principal balance of $91,156 and accrued interest of $40,917 is being disputed in court and negotiation for settlement. (See Note 13). ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. We signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge, and it is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2020 and 2019, the accrued interest is $4,769 and $3,755. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At December 31, 2020 and 2019, the outstanding principal balance is $50,000 and accrued interest is $62,167 and $49,967. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At December 31, 2020 and 2019, the outstanding principal balance is $50,000 and accrued interest is $55,367 and $43,166. ● A promissory note originally issued to an unrelated third party in August 2016 was restated in the amount of $282,983 bearing monthly interest at a rate of 2.0% and was due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock (See Note 7). We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for this debt discount was fully amortized during the years ended December 31, 2019 and 2018 for $3,616 and $329, respectively. During September 2019, the note of $282,983 plus accrued interest amended in December 2018 was restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. During September 2020, we issued a total of 10,000,000 restricted shares due to the default on repayments. The shares were valued at fair value of $6,000 (See Note 7).The common stock was valued at $5,895(See Note 7) and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount for the years ended December 31, 2020 and 2019 was $4,421 and $1,474 and debt discount at December 31, 2020 and 2019 is $0 and $4,421. The Note is in default and negotiation of settlement. At December 31, 2020 and 2019, the principal balance is $333,543, and the accrued interest is $106,511 and $25,127, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At December 31, 2020 and 2019, the principal balance outstanding is $15,000 and the accrued interest is $1,371. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2020 and 2019, the accrued interest is $51,667 and $39,466, respectively. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2020 and 2019, the accrued interest is $4,483 and $3,212, respectively. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. The Company repaid a total of $34,976, $42,698, and $44,478 during 2018, 2019 and 2020, respectively. At December 31, 2020 and 2019, the principal balance is $48,250 and $92,728, respectively. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At December 31, 2020 and 2019, the principal balance of the note is $50,000. ● During September 2018 and 2019, a promissory note originally issued to an unrelated third party in September 2017 was amended in the amount of $36,000 including original issuance discount of $6,000 each due in September 2019 and 2020. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Debt discounts have been fully amortized during 2019 for $7,500 for the restated Notes in September 2018 and 2019. Repayments of $7,000, $5,000, and $6,500 have been made during 2018, 2019, and 2020, respectively. The Note is under personal guarantee by Mr. Deitsch. At December 31, 2020 and 2019, the principal balance of the note is $29,500 and $30,000, net of debt discount of $1,500 and $4,500, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. ● During November 2018, a promissory note originally issued to an unrelated third party in October 2017 was restated in the amount of $60,000 including original issuance discount of $10,000 due May 2019. During July 2019, payment of original issuance discount of $10,000 was made. During September 2019, we issued additional 10,000,000 restricted shares due to the late payment of the original issuance discount of $10,000. The shares were valued at fair value of $4,000. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Debt discount and original issuance discount have been fully amortized during 2019 for $8,254. As of December 31, 2019, the amount due is $60,000. During January 2020, the Note of $60,000 and the Note of $76,076 (See Note 6(3)) plus accrued interest of $12,149 were combined and restated at a rate of 2.0% monthly due July 2020. During July 2020, the restated principal balance of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance of $166,926 carries interest at a rate of 2.0% monthly and was due January 2021. At December 31, 2020, the restated principal balance and accrued interest was $166,926 and $18,917. The principal balance plus accrued interest was further restated in February 2021 and was due in August 2021(See Note 13). The note is in default and in negotiation of settlement. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. During March 2020, $50,000 of the Note was settled for 125,000,000 shares with a fair value of $87,500. We recorded a loss on settlement in other expense for $37,500 (See Note 7). An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $32,200. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At December 31, 2020 and 2019, the principal balance of the loan is $84,000 and $120,000, respectively. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note is in default and in negotiation of settlement. The note was due in six months from the execution and funding of the note. At December 31, 2020 and 2019, the principal balance of the note is $18,000 and the accrued interest is $2,000. (3) At December 31, 2020 and 2019, the balance of $1,276,902 and $872,256 net of discount of $101,448 and $17,370, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During August 2018, a promissory note originally issued to an unrelated third party in July 2016 was restated in the amount of $76,076 bearing monthly interest at a rate of 2.5% and was due February 2019. The debt discount from 2018 has been fully amortized with the remaining $950 amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At December 31, 2019, the convertible note payable and accrued interest was recorded at $76,076 and $12,150, respectively. During January 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated. The principal balance plus accrued interest was further restated in July 2020 and February 2021 and is due in August 2021. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option. The note was due in six months from the execution and funding of the note. The loan is in default and in negotiation of settlement. At December 31, 2020 and 2019, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The total discount of $255,655 and original issuance discount of $62,950 have been fully amortized during 2019 for $28,421. During February 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. In connection with the issuance and restatements of the notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. During August 2020, the convertible promissory notes of $38,500 was amended to add additional original issuance discount (OID) of $7,550 due February 2021. During October 2020, a convertible promissory note of $16,500 was amended to add additional OID of $1,650 due April 2021.The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0005. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $123,900 on December 31, 2020 (See Note 8). The debt discounts associated with the warrants in August was for $38,500. The debt discounts associated with the warrants in October was for $16,500. The debt discounts are amortized over the life of the notes. Month of Issuance Number of Warrants Fair Value of Warrants Recorded as Debt Discount Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 August, 2020 92,100,000 $ 38,500 August, 2021 October, 2020 36,300,000 $ 16,500 October, 2022 During May 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During November 2019, we issued a convertible promissory note to an unrelated third party for $137,500 with original issuance discount of $12,500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.000275. The Note is in default and negotiation of settlement. During December 2019, we issued a convertible promissory note to an unrelated third party for $22,000 with original issuance discount of $2,000. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The Note is in default and negotiation of settlement. During 2019, repayments of $13,500 were made in cash to three of the Notes. Six of the Notes for a total of $87,100 were repaid in stocks as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019(see Note 7). Amortization for the year ended December 31, 2019 was $55,222. At December 31, 2019, the principal balance of the notes, net of discount of $17,370 was $736,180. The remaining debt discount of $17,370 has been fully amortized during the fiscal year 2020. Two of the above mentioned convertible notes payable for a total of $19,500 were settled in full in March and April 2021(See Note 13). During the year ended December 31, 2020, we issued convertible notes payable of $555,600 with original issuance discount of $53,600. $287,400 of these notes were due in a year, and $268,200 of the Notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0002 to 0.0008 per share. During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700 (See Note 7). In addition, in connection with the issuance of two of the above mentioned convertible notes of $57,500 with original issuance discount of $7,500 due in one year, the Company granted the 71,875,000 warrants at an exercise price of $0.002 per share that expire one year from the date of issuance. The warrants are valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The debt discounts associated with the warrants and OID for $50,000 and $7,500, respectively, are amortized over the life of the notes. Amortization for the year ended December 31, 2020 was $83,720. The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $65,634 using the Black-Scholes method on December 31, 2020 (See Note 8). At the date of this report, $1,121,700 of the above mentioned convertible notes payable are in default and in negotiation of settlement. At December 31, 2020, the principal balance of the notes, net of discount of $101,448 is $1,276,902. (4) At December 31, 2020 and 2019, the balance of $1,832,439 and $5,814,047 net of discount of $0 and $22,344, respectively, consisted of the following convertible loans: ● The remaining balance of $20,000 of a Convertible Note of $120,000 originated in March 2016 is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At December 31, 2020 and 2019, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $69,433 and $56,373, respectively. ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note was due on May 4, 2018. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. We have accrued interest at default interest rate of 20% after the note’s maturity date. After prior conversions, during December 2019, the principal balance of $16,752 with accrued interest of $3,232 previously assigned and sold to a third party in February 2018 was settled as part of issuances of 800,000,000 shares of common stocks (See Note 7). At December 31, 2020 and 2019, the remaining principal of $12,629 and $29,381 plus accrued interest of $12,308 and $9,782, at fair value, was recorded at $49,875 and $62,253, respectively. The remaining principal balance of the Note is in default. All of the convertible notes discussed below are with a single unrelated third party. ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019 (See Note 7). The new note of $49,819 carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. The conversion discount was further decreased to fifty percent due to the default on the Note. During September 2018, the Noteholder made a conversion of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At December 31, 2019, the convertible note payable with principal balance of $38,301, at fair value, was recorded at $246,819. ● During February 2018, we issued a convertible debenture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At December 31, 2019, the convertible note payable with principal balance of $220,000, at fair value, was recorded at $1,412,175. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At December 31, 2019, the convertible note payable with principal balance of $71,500, at fair value, was recorded at $458,957. ● During March 2018, we issued a convertible debenture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in March 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At December 31, 2019, the convertible note payable with principal balance of $66,000, at fair value, was recorded at $417,576. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. ● During June 2018, the $60,000 Back-end Note was funded. The note carries interest at 8% and was due in March 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At December 31, 2019, the convertible note payable with principal balance of $66,000, at fair value, was recorded at $417,577. ● During May 2018, we issued a convertible debenture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in May 2019, unless previously converted into shares of restricted common stock. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At December 31, 2019, the convertible note payable with principal balance of $60,000, at fair value, was recorded at $369,372. ● During August 2018, we issued a convertible debenture in the amount of $31,500 to an unrelated third party. The note carries interest at 8% and was due in August 2019, unless previously converted into shares of restricted common stock. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At December 31, 2019, the convertible note payable with principal balance of $31,500, at fair value, was recorded at $183,565. All of the above convertible notes with principal balance of a total of $511,319 as of December 31, 2019, plus the additional principal increases due to the default terms, were settled in October 2020. During September 2020, the Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345 (See Note 7). During October 2020, the Note holder sold the remaining debt principal value as of October 22, 2020 of $509,301 and accrued interest of $234,417 for $250,000 to a non-related party. Based on the conversion methodology, the debt was valued at $1,859,294 prior to conversion, and the Company recorded a gain on settlement of $1,609,294, which is recorded within gain (loss) on settlement of debt, net, within the statement of operations. Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691 ● The new note of $250,000 carries interest at 8%. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. In connection with the issuance of the convertible note payable, we recorded a day
Schedule of Future Minimum Principal Payment	At December 31, 2020, the future minimum principal payments for the above mentioned PPP and EIDL loans are as follows: Years Amount 2021 $ 10,725 2022 56,290 2023 3,283 2024 3,408 2025 3,538 Thereafter 137,551 $ 214,795

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000 Number of Fair Value of Date shares converted Debt 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691

Stock Warrants (Tables)

Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Warrants Issued	The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Month of Issuance Number of Warrants Fair Value of Month of February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 Fair Value of Month of Issuance Number of Warrants Warrants Month of Expiration August, 2020 92,100,000 $ 38,500 August, 2021 October, 2020 36,300,000 $ 16,500 October, 2022
Summary of Warrants Outstanding	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2020 and 2019: Number Of Weighted Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 154,000,000 0.001 Expired (114,100,000 ) 0.0027 Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued 200,275,000 0.0014 Expired (50,000,000 ) 0.0015 Balance December 31, 2020 202,775,000 $ 0.0017
Summary of Fixed Price Warrants Outstanding	The following table summarizes information about fixed-price warrants outstanding as of December 31, 2020 and 2019 : Exercise Price Weighted Average Number Outstanding Weighted Weighted 2020 $ 0.001-0.03 51,086,612 0.93 years $ 0.0017 2019 $ 0.001-0.03 10,187,671 0.62 years $ 0.0028

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Taxes Tables Abstract
Schedule of Effective Income Tax Rate Reconciliation	The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2020 and 2019, (computed by the following blended rate), are approximately as follows. 2020 2019 Tax Rate Reconciliation: Federal tax rate 21.00 % 21.00 % Add: State taxes 5.50 % 5.50 % Permanent difference -1.15 % -1.15 % Valuation allowance -25.35 % -25.35 % Tax rate - -
Schedule of Income Tax Expense	December 31, 2020 2019 Computed “expected” tax expense (benefit) - Federal $ (161,529 ) (1,384,203 ) Computed “expected” tax expense (benefit) - State (33,421 ) (286,398 ) Permanent differences (145,667 ) 1,313,998 Change in valuation allowance 340,617 356,603 Provision for income taxes $ - $ -
Schedule of Deferred Income Tax Assets	2020 2019 Net deferred income tax assets: Reserve for prepaid inventory $ 23,573 $ 18,174 Accrued salary 362,356 316,659 Reserve(recovery) for receivables from officer (25,979 ) 14,954 Net operating loss carryforwards 9,729,342 9,398,889 Valuation allowance (10,089,292 ) (9,748,676 ) Net deferred income tax asset $ - $ -

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: December 31, 2020 2019 Accrued consulting fees $ 166,900 $ 161,550 Accrued settlement expenses 35,000 35,000 Accrued payroll taxes 215,581 167,906 Accrued interest 351,830 231,186 Accrued others 11,121 16,905 Total $ 780,432 $ 612,547

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses	Prepaid expenses and other current assets consist of the following: December 31, December 31, Supplier advances for future purchases $ 246,162 $ 224,859 Reserve for supplier advances (246,162 ) (224,859 ) Net supplier advances - - Prepaid professional fees 10,000 8,650 Deferred stock compensation - 8,500 Total $ 10,000 $ 17,150

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Cost and Balance Sheet Information	December 31, December 31, 2020 2019 Lease cost Operating lease cost $ 89,021 $ 89,021 Short-term lease cost 18,698 45,026 Total lease cost $ 107,719 $ 134,047 Balance sheet information Operating ROU Assets $ 144,010 $ 207,530 Operating lease obligations, current portion 82,873 73,278 Operating lease obligations, non-current portion 60,447 143,322 Total operating lease obligations $ 143,320 $ 216,600 Weighted average remaining lease term (in years) – operating leases 1.67 2.67 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows, for the years ended December 31, 2020 and 2019: Cash paid for amounts included in the measurement of operating lease liabilities $ 98,780 $ 79,950
Schedule of Future Minimum Payments Under Lease Agreements	Future minimum payments under these lease agreements are as follows: December 31, Total 2021 91,379 2022 62,274 Total future lease payments $ 153,653 Less imputed interest 10,333 Total $ 143,320

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2020
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000 Number of Fair Value of Date shares converted Debt 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691
Convertible Notes Payable [Member]
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated deficit			$ (68,633,468)	$ (67,864,284)
Working capital			11,427,256	(10,931,827)
Stockholders' deficit			(11,493,815)	(11,701,035)	$ (5,936,593)
Accounts receivable written off				2,789
Allowance for doubtful account
Change in reserve for supplier advances for purchases			21,303	23,948
Inventory valuation allowance			246,162	224,859
Provision for income taxes
Minimum [Member]
Property and equipment estimated useful lives			3 years
Maximum [Member]
Property and equipment estimated useful lives			7 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration risk, percentage			37.00%	55.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration risk, percentage				12.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration risk, percentage			100.00%	100.00%
SBA Loan Agreement [Member]
Proceeds form loan	$ 150,000	$ 150,000

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive securities excluded from computation of earnings per share	4,533,176,373	13,350,194,779
Options and Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	202,775,000	52,500,000
Convertible Notes Payable at Fair Value [Member]
Antidilutive securities excluded from computation of earnings per share	1,515,706,865	11,672,780,512
Convertible Notes Payable [Member]
Antidilutive securities excluded from computation of earnings per share	2,814,694,508	1,624,914,267

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative)	Dec. 31, 2020
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants outstanding, measurement input, percentage	0.10
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants outstanding, measurement input, percentage	0.0159
Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrants outstanding, measurement input, percentage	2.76
Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrants outstanding, measurement input, percentage	3.48
Measurement Input, Expected Dividend Rate [Member]
Warrants outstanding, measurement input, percentage	0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Warrant liability	$ 189,543	$ 1,411
Derivative liabilities	3,377,633	834,457
Convertible notes at fair value	1,832,439	5,814,047
Fair Value, Inputs, Level 1 [Member]
Warrant liability
Derivative liabilities
Convertible notes at fair value
Fair Value, Inputs, Level 2 [Member]
Warrant liability
Derivative liabilities	3,377,633	834,457
Convertible notes at fair value
Fair Value, Inputs, Level 3 [Member]
Warrant liability	189,543	1,411
Derivative liabilities
Convertible notes at fair value	$ 1,832,439	$ 5,814,047

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Convertible Notes Payable [Member]
Beginning balance		$ 5,814,047	$ 1,156,341
Purchases, issuances, and settlements		25,981	688,274
Day one loss on value of hybrid instrument	[1]	318,174	926,109
Loss (gain) from change in fair value	[1]	(1,931,927)	3,423,935
Gain on settlement		(1,609,294)
Debt discount		22,344	(22,344)
Settlement through issuance of common stock			(83,268)
Repayments in cash		(5,782)
Conversion to common stock		(801,104)	(275,000)
Ending balance		1,832,439	5,814,047
Warrants [Member]
Beginning balance		1,411	1,468
Purchases, issuances, and settlements		143,369
Total loss (gain) included in earnings	[2]	44,763	(57)
Ending balance		$ 189,543	$ 1,411
[1]	The (gains) losses related to the valuation of the convertible notes are included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations.
[2]	The gain related to the revaluation of our warrant liability is included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations.

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Assumptions and the Significant Terms (Details) - Convertible Notes Payable [Member]	12 Months Ended
	Dec. 31, 2020USD ($)d$ / shares	Dec. 31, 2019USD ($)d$ / shares
Face Amount | $	$ 766,101	$ 1,244,204
Minimum [Member]
Conversion Price | $ / shares	$ 0.00050	$ 0.00010
Percentage of stock price for look-back period	50.00%	50.00%
Look-back period | d	3	3
Maximum [Member]
Conversion Price | $ / shares	$ 0.00064	$ 0.000293
Percentage of stock price for look-back period	60.00%	60.00%
Look-back period | d	25	25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Long-term debt, measurement input	0.08	0.08
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Long-term debt, measurement input	0.10	0.10
Measurement Input, Default Interest Rate [Member] | Minimum [Member]
Long-term debt, measurement input	0.20	0.20
Measurement Input, Default Interest Rate [Member] | Maximum [Member]
Long-term debt, measurement input	0.24	0.24
Measurement Input, Discount Rate [Member]
Long-term debt, measurement input

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw Materials	$ 78,880	$ 52,183
Finished Goods	5,271	8,177
Total Inventories	84,151	60,360
Less: Long-term inventory	(78,880)	(52,183)
Current portion	$ 5,271	$ 8,177

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 3,831	$ 3,737

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property and equipment, gross	$ 227,843	$ 216,033
Less: Accumulated depreciation	(213,101)	(209,270)
Property and equipment, net	14,742	6,763
Computer Equipment [Member]
Property and equipment, gross	25,120	25,120
Furniture and Fixtures [Member]
Property and equipment, gross	34,757	34,757
Lab Equipment [Member]
Property and equipment, gross	65,521	53,711
Telephone Equipment [Member]
Property and equipment, gross	12,421	12,421
Office Equipment - Other [Member]
Property and equipment, gross	16,856	16,856
Leasehold Improvements [Member]
Property and equipment, gross	$ 73,168	$ 73,168

Due to_from Officer (Details Na

Due to/from Officer (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Due to officer	$ 200,837	$ 122,812
Repayment of officers loans	22,150	134,015
Loans from officer	254,000	5,000
Accrued interest expense for amount due to officer	7,675	6,330
Bad debt recovery related party	(161,500)	61,789
Company other receivable reserves	402,970	564,470
Bad debt expense		61,789
Rik Deitsch [Member]
Due to officer	$ 200,837	$ 122,812
Bears interest percentage	4.00%	4.00%
Repayment of officers loans	$ 22,150	$ 134,015
Loans from officer	254,000	5,000
Accrued interest expense for amount due to officer	$ 7,675	6,330
Bad debt expense		$ 59,000

Debts - Schedule of Debt (Detai

Debts - Schedule of Debt (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Note payable- Related Party		$ 14,400
Notes payable - Unrelated third parties (Net of discount of $1,500 and $8,921, respectively)	1,346,057	1,385,163
Convertible notes payable - Unrelated third parties (Net of discount of $101,448 and $17,370, respectively)	1,276,902	872,256
Convertible notes payable, at fair value (Net of discount of $0 and $22,344, respectively)	1,832,439	5,814,047
Other advances from an unrelated third party	225,000	175,000
SBA notes payable	214,795
Ending balances	4,895,193	8,260,866
Less: Long-term portion-Convertible Notes payable-Unrelated third parties	(48,477)	(907,912)
Less: Long-term portion- SBA notes payable	(204,070)
Current portion	$ 4,642,646	$ 7,352,954

Debts - Schedule of Debt (Det_2

Debts - Schedule of Debt (Details) (Parenthetical)	Dec. 31, 2021USD ($)	Aug. 28, 2021USD ($)	Oct. 05, 2020USD ($)shares	Sep. 21, 2020USD ($)shares	Feb. 18, 2020USD ($)shares	Jan. 21, 2020USD ($)shares	Jun. 06, 2019USD ($)shares	May 31, 2019USD ($)shares	May 06, 2019USD ($)shares	Feb. 15, 2019USD ($)	Jul. 31, 2017USD ($)	Mar. 19, 2014USD ($)	Dec. 31, 2021USD ($)	Apr. 30, 2021USD ($)	Mar. 31, 2021USD ($)$ / shares	Feb. 28, 2021USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Oct. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Aug. 31, 2020USD ($)shares	Jul. 31, 2020USD ($)$ / sharesshares	Apr. 30, 2020USD ($)	Jan. 31, 2020USD ($)	Jan. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares	May 31, 2019USD ($)shares	Feb. 28, 2019USD ($)$ / sharesshares	Jan. 31, 2019USD ($)	Dec. 31, 2018USD ($)shares	Sep. 30, 2018USD ($)	Aug. 31, 2018USD ($)d	Jul. 31, 2018USD ($)d	Jun. 30, 2018USD ($)	May 31, 2018USD ($)d	Apr. 30, 2018USD ($)d	Mar. 31, 2018USD ($)	Feb. 28, 2018USD ($)d	Sep. 30, 2017USD ($)	May 31, 2017USD ($)d	Apr. 30, 2017USD ($)shares	Dec. 31, 2016USD ($)dshares	Jun. 30, 2012USD ($)	Feb. 29, 2020USD ($)shares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Mar. 31, 2019USD ($)	Mar. 31, 2012USD ($)shares	Dec. 31, 2021USD ($)shares	Sep. 30, 2019USD ($)	Dec. 31, 2020USD ($)d$ / sharesshares	Dec. 31, 2019USD ($)d$ / sharesshares	Dec. 31, 2018USD ($)	Sep. 30, 2021$ / shares	Nov. 30, 2019USD ($)$ / shares	Jul. 31, 2019USD ($)	Jun. 17, 2019USD ($)shares	Nov. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Nov. 30, 2017USD ($)	Oct. 31, 2017USD ($)	Aug. 31, 2017	Jun. 30, 2017USD ($)	Oct. 31, 2016USD ($)	Sep. 26, 2016USD ($)	Aug. 31, 2016USD ($)shares	May 31, 2016USD ($)	Apr. 30, 2016USD ($)	Mar. 28, 2016USD ($)	Apr. 30, 2014$ / sharesshares	Aug. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2011USD ($)	Aug. 15, 2011USD ($)	Aug. 02, 2011USD ($)	Dec. 31, 2010USD ($)	Feb. 28, 2010	Jan. 31, 2010
Notes payable																	$ 4,895,193								$ 8,260,866																				$ 8,260,866	$ 4,895,193						$ 4,895,193	$ 8,260,866
Interest expense, debt																																																				316,207	244,278
Debt conversion, converted instrument, shares issued | shares			107,817,770	107,133,333	250,000,000	250,000,000	250,000,000	250,000,000	250,000,000
Repayments of notes payable																																																				14,400
Gain loss on extinguishment of debt																																																				1,587,293	92,621
Repayments of convertible debt																																																				5,782	13,500
Amortization of debt discount																																																				130,485	100,810
Debt instrument accrued interest																																																				$ 30,850	$ 66,460
Common stock, shares, issued | shares																	6,955,197,214								5,876,746,111																	1,000,000			5,876,746,111	6,955,197,214						6,955,197,214	5,876,746,111
Common stock issued value																	$ 6,955,197								$ 5,876,746																				$ 5,876,746	$ 6,955,197						$ 6,955,197	$ 5,876,746
Number of warrants issued | shares																																																																							100,000
Month of expiration																																																																							Apr. 9, 2019
Fair Value of Warrants																		$ 16,500		$ 20,848					$ 7,370			$ 8,147																										$ 0
Warrant exercise price | $ / shares																																																																							$ 0.025
Stock issued price per shares | $ / shares																	$ 0.18								$ 0.18																				$ 0.18	$ 0.18						$ 0.18	$ 0.18
Number of shares issued for conversion of debt			$ 64,691	$ 171,413	$ 275,000	$ 150,000	$ 100,000	$ 100,000	$ 75,000
Proceeds from issuance of other long term debt																																																				$ 50,000	$ 175,000
Other advances from an unrelated third party																	$ 225,000								$ 175,000																				$ 175,000	$ 225,000						$ 225,000	$ 175,000
Warrants [Member]
Debt discount																		$ 7,500
Number of warrants issued | shares																	123,900																													123,900						123,900
Warrant exercise price | $ / shares																		$ 0.002
Minimum [Member]
Warrant exercise price | $ / shares																	$ 0.001								$ 0.001																				$ 0.001	$ 0.001						$ 0.001	$ 0.001
Maximum [Member]
Warrant exercise price | $ / shares																	$ 0.03								$ 0.03																				$ 0.03	$ 0.03						$ 0.03	$ 0.03
Non Related Party Ten [Member]
Notes payable																	$ 84,000																													$ 84,000						$ 84,000
Debt discount																	14,000																													14,000						14,000
Settlement Agreement [Member] | Non Related Party Ten [Member]
Cash settlement																	$ 84,000																													$ 84,000						$ 84,000
SBA Loan Agreement [Member]
Debt instrument, interest rate																	3.75%																													3.75%						3.75%
Outstanding notes payable																	$ 150,000																													$ 150,000						$ 150,000
Repayments of convertible debt																																														5,000
Debt conversion principle amount																																														731
Proceeds from issuance of other long term debt																						$ 64,895
Promissory Note [Member] | Unrelated Third Party [Member]
Notes payable																	18,917						$ 76,076	$ 76,076	$ 60,000																				$ 60,000	18,917						18,917	$ 60,000						$ 60,000
Debt instrument, interest rate																					2.00%		2.00%	2.00%
Debt discount																										$ 10,000																									$ 10,000						$ 10,000		10,000
Accrued interest																							$ 12,149
Debt principal amount																	166,926				$ 148,225																									166,926						166,926
Interest payable																					18,701
Stock issued during period, restricted stock | shares																										10,000,000
Restricted stock options fair value																										$ 4,000
Mr. Deitsch [Member] | Unrelated Third Party [Member]
Debt discount																																																											$ 8,254
Convertible Debtentures [Member]
Debt discount																	101,448								17,370																				17,370	101,448						101,448	17,370
Outstanding notes payable																	1,276,902								872,256																				872,256	1,276,902						1,276,902	872,256
Convertible Debtentures [Member] | Non Related Party Twelve [Member]
Convertible notes payable												$ 500,000
Repayments of convertible debt												$ 15,000
Debt instrument convertible debt percentage												8.00%
Convertible Debtentures [Member] | Non Related Party Thirteen [Member]
Accrued interest																																																						11,412
Gain loss on extinguishment of debt																																																						38,412
Convertible notes payable												$ 1,000,000																1,000,000		$ 27,000																								27,000
Repayments of convertible debt												$ 30,000																																										3,000
Debt instrument convertible debt percentage												8.00%
Convertible Debtentures [Member] | Non Related Party Fourteen [Member]
Convertible notes payable																									76,076							$ 76,076													76,076								76,076
Debt instrument convertible debt percentage																																2.50%
Amortization of debt discount																																																$ 950
Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate																																										12.00%
Accrued interest																																						$ 2,820
Convertible notes payable																														32,400												$ 110,000												32,400
Debt maturity date																																										Sep. 8, 2017
Debt conversion principle amount																																						$ 46,999
Conversion percentage																																										60.00%
Trading days | d																																										25
Note Holder [Member]
Debt conversion, converted instrument, shares issued | shares																								75,000,000
Back and End Note [Member]
Debt instrument, interest rate																																				8.00%
Debt principal amount																									71,500											$ 100,000									71,500								71,500
Convertible notes payable																									458,957											$ 65,000									458,957								458,957
Debt instrument convertible debt percentage																																				24.00%
Conversion percentage																																				60.00%
Trading days | d																																				25
Derivative loss																																				$ 110,700
Back and End Note [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate																																		8.00%
Debt principal amount																									66,000																				66,000								66,000
Convertible notes payable																									417,577									$ 60,000											417,577								417,577
Debt instrument convertible debt percentage																																		24.00%
Conversion percentage																																		60.00%
Restatement of Promissory Notes [Member]
Debt principal amount																					166,926
Restatement of Promissory Notes [Member] | Subsequent Event [Member]
Debt instrument accrued interest																$ 23,258
PPP [Member]
Proceeds from issuance of other long term debt																																																				225,000
Note Payable One [Member]
Interest expense, debt																																																				19,967	17,747
Note Payable One [Member] | Promissory Note [Member]
Notes payable																	14,400								14,400					12,000															14,400	14,400						$ 14,400	14,400	12,000						$ 12,000
Debt instrument, unamortized discount net issuance costs																									0					2,400															0								0	2,400						$ 2,000
Debt conversion, converted instrument, shares issued | shares																																																				5,000,000
Debt instrument fair value																	3,000																													3,000						$ 3,000
Outstanding notes payable																	0								14,400																				14,400	0						0	14,400
Note Payable One [Member] | Director [Member]
Notes payable																																																																													$ 200,000
Debt instrument, interest rate																																																																														12.00%	10.00%
Accrued interest																																																				179,522	159,555
Note Payable Two [Member]
Notes payable																	1,346,057								1,385,163																				1,385,163	1,346,057						1,346,057	1,385,163
Debt instrument, unamortized discount net issuance costs																	1,500								8,921																				8,921	1,500						1,500	8,921
Note Payable Two [Member] | UniversityCentreWestLtdMember
Debt instrument rent expenses																																																																									$ 55,410
Note Payable Two [Member] | Related Party [Member]
Notes payable																																										$ 50,000																										$ 75,000
Debt instrument, interest rate																																										2.00%																										2.00%
Accrued interest																																																				62,167	49,967
Repayments of notes payable																																									$ 25,000
Debt principal amount																	50,000								50,000																				50,000	50,000						50,000	50,000
Common stock, shares, issued | shares																																									5,000,000
Note Payable Two [Member] | Related Party One [Member]
Accrued interest																																																				55,367	43,166
Debt principal amount																	50,000								50,000																				50,000	50,000						50,000	50,000
Note Payable Two [Member] | Non Related Party Two [Member]
Debt discount																	0								4,421																				4,421	0						0	4,421					$ 3,945
Accrued interest																																																						282,983
Debt instrument, unamortized discount net issuance costs																									3,616					329															3,616								3,616	329
Amortization of debt discount																																																				4,421	1,474	4,421
Common stock, shares, issued | shares																																																										10,000,000
Note Payable Two [Member] | Non Related Party Two [Member]
Notes payable																	333,543																													333,543						333,543
Debt discount																	$ 5,895																													$ 5,895						$ 5,895
Common stock, shares, issued | shares																	20,000,000																													20,000,000						20,000,000
Note Payable Two [Member] | NonRelatedPartyFiveMember
Notes payable											$ 200,000																																																					$ 12,500
Debt instrument, interest rate																																																															15.00%	10.00%
Accrued interest																																																				$ 4,483	3,212
Note Payable Two [Member] | Non Related Party Ten [Member]
Notes payable																									120,000																				120,000		$ 50,000						120,000
Debt discount																																															20,000
Debt instrument, unamortized discount net issuance costs																																															120,000
Note Payable Two [Member] | Non Related Party Eleven [Member]
Notes payable																																															50,000														$ 18,000
Debt discount																																															20,000
Debt instrument, unamortized discount net issuance costs																																															$ 120,000														3,000
Common stock, shares, issued | shares																																															125,000,000
Common stock issued value																																															$ 87,500
Note Payable Two [Member] | Southridge Partners, LLP [Member]
Notes payable																																																																								$ 281,772
Noncash transaction, value consideration received																																											$ 281,772
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Two [Member]
Notes payable																	$ 333,543								333,543																				333,543	$ 333,543						333,543	333,543
Accrued interest																																																				106,511	25,127
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Four [Member]
Accrued interest																																																				51,667	39,466
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member]
Notes payable																	48,250								92,728																				92,728	48,250						48,250	92,728
Repayments of notes payable																																		$ 5,000																		44,478	42,698	34,976
Repayments of lines of credit																																		2,000
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member] | Subsequent Event [Member]
Outstanding notes payable														$ 33,874
Cash settlement														130,401
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Eleven [Member]
Accrued interest																																																				2,000	2,000
Repayments of notes payable																																																				18,000	18,000
Note Payable Two [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Notes payable																																																																											$ 50,000	$ 350,000
Repayments of lines of credit																																																	$ 25,000
Debt principal amount																																																																										$ 175,000
Non-payment penalty charges																																																																										$ 25,000
Sale of stock, number of shares | shares																																																	142,858
Note Payable Two [Member] | Promissory Note [Member]
Notes payable																																																																					$ 10,000
Debt instrument, interest rate																																																																					10.00%
Debt instrument accrued interest																																																				4,769	3,755
Note Payable Two [Member] | Promissory Note [Member] | NonRelatedPartyOneMember
Notes payable																																																										$ 282,983									$ 282,983
Debt instrument, interest rate																																																										2.00%									2.00%
Debt discount																																																																			$ 2,765
Common stock, shares, issued | shares																																																																			2,000,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Three [Member]
Notes payable																	15,000								15,000				$ 60,000																15,000	15,000						15,000	15,000													$ 75,000
Debt instrument, interest rate																																																																		10.00%
Accrued interest																																																				1,371	1,371
Debt principal amount																																					$ 15,000
Debt instrument accrued interest																													15,900
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Four [Member]
Notes payable																																																																	$ 50,000
Debt instrument, interest rate																																																																	2.00%
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Seven [Member]
Notes payable											50,000						50,000								50,000																				50,000	50,000						50,000	50,000
Amortization of debt discount											$ 10,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member]
Notes payable															$ 30,000		29,500		$ 33,000						30,000														$ 36,000						30,000	29,500						29,500	30,000
Debt instrument, interest rate															12.00%
Debt discount																	1,500								4,500																				4,500	1,500						1,500	4,500
Accrued interest																			3,000																																		4,500	6,000
Debt instrument, unamortized discount net issuance costs																			6,000							6,000					$ 6,000								6,000												6,000
Debt instrument convertible price per share | $ / shares															$ 0.01
Repayments of notes payable															$ 1,000				$ 6,500							$ 5,000					$ 7,000								$ 1,500
Amortization of debt discount																																																					7,500	4,000
Note Payable Two [Member] | Promissory Note [Member] | Unrelated Third Parties [Member] | Subsequent Event [Member]
Notes payable															33,000
Debt instrument, unamortized discount net issuance costs															$ 3,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Ten [Member]
Notes payable																	70,000																													70,000						70,000									120,000
Debt discount																	14,000																													14,000						14,000
Debt instrument, unamortized discount net issuance costs																																																													$ 20,000
Cash settlement																	$ 37,500																													$ 37,500						$ 37,500
Common stock, shares, issued | shares																	36,000,000																													36,000,000						36,000,000
Common stock issued value																	$ 32,200																													$ 32,200						$ 32,200
Note Payable Two [Member] | Promissory Note Two [Member]
Notes payable										$ 101,818
Accrued interest																																																				40,917	50,971
Outstanding notes payable																	91,156																													91,156						91,156
Repayments of lines of credit																																																				13,500	75,000
Debt settlement																																															$ 88,500
Gain loss on extinguishment of debt																																																				$ 15,500	18,841
Stock issued during period, restricted stock | shares																																																				10,000,000
Note Payable Two [Member] | Promissory Note Two [Member] | Scheduled Payments Through May 1, 2020 [Member]
Accrued interest										21,023
Repayments of lines of credit										$ 104,000
Note Payable Two [Member] | Promissory Note Two [Member] | Settlement [Member]
Accrued interest																																																				$ 40,917
Note Payable Two [Member] | Reverse Stock Split [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Non-payment penalty charges																																																																									350,000
Sale of stock, number of shares | shares																																																	5,714,326
Cash settlement																																																																									450,000
Debt default, amount																																																																									$ 100,000
Note Payable Two [Member] | Director [Member] | Promissory Note Two [Member]
Notes payable																	$ 91,156								$ 160,633					192,974															$ 160,633	$ 91,156						$ 91,156	$ 160,633	192,974													$ 200,000
Debt instrument, interest rate																																																																			12.00%
Accrued interest																																																						40,033
Note Payable Two [Member] | Former Director [Member] | Promissory Note Two [Member]
Notes payable																																																																			$ 100,000
Note Payable Two [Member] | Two Unrelated Parties [Member] | Settlement Agreement [Member]
Repayments of notes payable																																		130,401
Repayments of lines of credit																																		$ 40,000
Convertible Notes Payable [Member]
Debt discount																												5,000
Convertible notes payable																												$ 70,000
Debt instrument convertible debt percentage																												0.05%
Amortization of debt discount																											$ 8,200
Debt instrument accrued interest																		$ 166,168
Fair Value of Warrants																		8,633
Convertible Notes Payable [Member] | Warrants [Member]
Debt discount																		$ 29,481
Number of warrants issued | shares																		36,300,000		92,100,000					44,000,000			110,000,000																	44,000,000								44,000,000
Month of expiration																		Oct. 31, 2022		Aug. 31, 2021					Aug. 31, 2020			Aug. 31, 2019																	Aug. 31, 2020								Aug. 31, 2020
Fair Value of Warrants																		$ 16,500		$ 38,500					$ 7,370			$ 8,147
Warrant exercise price | $ / shares																		$ 0.001
Convertible Notes Payable [Member] | Common Stock [Member]
Debt instrument, unamortized discount net issuance costs								$ 6,400																			$ 6,400
Common stock, shares, issued | shares								6,000,001																			6,000,001
Common stock issued value								$ 1,800																			$ 1,800
Convertible Notes Payable [Member] | Minimum [Member]
Debt instrument convertible price per share | $ / shares																	$ 0.00050								$ 0.00010																				$ 0.00010	$ 0.00050						$ 0.00050	$ 0.00010
Conversion percentage																																																				50.00%	50.00%
Trading days | d																																																				3	3
Convertible Notes Payable [Member] | Maximum [Member]
Debt instrument convertible price per share | $ / shares																	$ 0.00064								$ 0.000293																				$ 0.000293	$ 0.00064						$ 0.00064	$ 0.000293
Conversion percentage																																																				60.00%	60.00%
Trading days | d																																																				25	25
Convertible Notes Payable [Member] | Subsequent Event [Member] | Minimum [Member]
Debt instrument convertible price per share | $ / shares															$ 0.0003																																								$ 0.0008
Convertible Notes Payable [Member] | Subsequent Event [Member] | Maximum [Member]
Debt instrument convertible price per share | $ / shares															$ 0.002																																								$ 0.002
Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Notes payable																	$ 555,600																													$ 555,600						$ 555,600
Debt discount																		$ 1,650		7,550
Debt instrument, unamortized discount net issuance costs																									$ 2,000																				$ 2,000								$ 2,000			$ 12,500
Debt principal amount																		16,500		38,500
Convertible notes payable																									$ 22,000																				$ 22,000								$ 22,000			$ 137,500
Stock issued price per shares | $ / shares																									$ 0.0002																				$ 0.0002								$ 0.0002			$ 0.000275
Amortization																																																					$ 55,222
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Minimum [Member]
Notes payable																	$ 268,200																													$ 268,200						268,200
Amortization of debt discount																																																				$ 53,600
Stock issued price per shares | $ / shares																	$ 0.0002																													$ 0.0002						$ 0.0002
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Maximum [Member]
Notes payable																	$ 268,200																													$ 268,200						$ 268,200
Amortization of debt discount																																																				$ 287,400
Stock issued price per shares | $ / shares																	$ 0.0008																													$ 0.0008						$ 0.0008
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Subsequent Event [Member]
Repayments of convertible debt													$ 19,500	$ 19,500
Convertible Notes Payable [Member] | Non Related Party Fourteen [Member]
Accrued interest																																																					12,150
Convertible notes payable																							$ 60,000	$ 60,000
Convertible Notes Payable [Member] | Non Related Party Fifteen [Member]
Debt instrument, unamortized discount net issuance costs																																																														$ 10,000
Convertible notes payable																																																														$ 60,000
Convertible Notes Payable [Member] | Non Related Party Twenty [Member]
Notes payable																									$ 255,655																				$ 255,655								255,655
Debt discount																									62,950																				62,950								62,950
Debt instrument, unamortized discount net issuance costs																														62,950																								62,950
Convertible notes payable																														$ 618,250																								$ 618,250
Amortization of debt discount																																																					28,421
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Minimum [Member]
Debt instrument convertible debt percentage																														0.03%																								0.03%
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Maximum [Member]
Debt instrument convertible debt percentage																														0.10%																								0.10%
Convertible Notes Payable [Member] | 16 Unrelated Third Parties [Member]
Debt discount																									17,370																				17,370								17,370
Convertible notes payable																									736,180																				736,180								736,180
Amortization																																																				$ 17,370
Convertible Notes Payable [Member] | Unrelated Third Party [Member]
Accrued interest																									$ 3,232																											12,308	9,782
Debt conversion, converted instrument, shares issued | shares																									800,000,000
Debt principal amount																	$ 12,629	250,000							$ 29,381																				29,381	$ 12,629						12,629	29,381
Convertible notes payable																	49,875								62,253															$ 64,000					62,253	49,875						49,875	62,253
Debt instrument convertible debt percentage																																								20.00%
Debt maturity date																																								May 4, 2018
Conversion percentage																																								60.00%
Trading days | d																																								20
Convertible Notes Payable [Member] | Brewer and Associates Consulting, LLC [Member] | Non Related Party Twenty [Member]
Debt principal amount																	20,000								20,000																				20,000	20,000						20,000	20,000
Convertible notes payable																	69,433								56,373																				56,373	69,433						69,433	56,373																	$ 120,000
Debt instrument convertible debt percentage																																																																						55.00%
Derivative, collateral, obligation to return cash																																																																						$ 36,000
Convertible Notes Payable [Member] | Note Agreement [Member]
Debt principal amount																												1,000,000
Proceeds from loan																																																				392,573
Convertible Notes Payable [Member] | Note Agreement [Member] | Subsequent Event [Member]
Debt instrument fair value	$ 2,344,399												$ 2,344,399																																					$ 2,344,399
Stock issued during period, restricted stock | shares																																																		240,350,000
Stock issued during period, restricted stock value																																																		$ 120,175
Proceeds from loan	$ 80,738	$ 86,520
Convertible Notes Payable [Member] | Promissory Note [Member]
Debt principal amount																													75,000
Interest payable																													15,900
Convertible notes payable																													60,000
Derivative loss																													75,900
Convertible Notes Payable [Member] | Promissory Note [Member] | Settlement Agreement [Member] | Non Related Party Fifteen [Member]
Convertible notes payable																	60,000								60,000																				60,000	60,000						60,000	60,000
Convertible Notes Payable [Member] | Convertible Debtentures [Member]
Debt instrument, interest rate																																										8.00%
Debt principal amount																	38,301								38,301																				38,301	38,301						38,301	38,301
Convertible notes payable																	112,528								246,819																	$ 49,819			246,819	112,528						112,528	246,819
Debt instrument convertible debt percentage																																										24.00%
Debt maturity date																																										Feb. 13, 2019
Conversion percentage																																										60.00%
Trading days | d																																										25
Convertible Notes Payable [Member] | Convertible Promissory Note [Member]
Debt discount																		1,650
Convertible notes payable																		$ 16,500		$ 38,500
Debt instrument convertible debt percentage																		0.05%		0.05%
Debt discount, warrant																		$ 16,500		$ 38,500
Convertible Notes Payable [Member] | Note Holder [Member]
Notes payable																	1,276,902																													1,276,902						1,276,902
Debt discount																	101,448				7,500																									101,448						101,448
Debt instrument fair value																					700
Repayments of notes payable																					22,000
Convertible notes payable																	1,121,700				57,500																									1,121,700						1,121,700
Debt discount, warrant																					$ 50,000
Amortization of debt discount																																																				83,720
Stock issued during period, restricted stock | shares																					1,000,000
Number of warrants issued | shares																					71,875,000
Fair Value of Warrants																					$ 65,634
Warrant exercise price | $ / shares																					$ 0.002
Convertible Notes Payable [Member] | Convertible Debenture [Member] | Restricted Stock [Member]
Debt conversion, converted instrument, shares issued | shares																														52,244,433
Debt principal amount																														$ 15,000																								$ 15,000
Number of shares issued for conversion of debt																														$ 37,011
Convertible Notes Payable [Member] | Restatement of Promissory Notes [Member]
Repayments of convertible debt																													$ 75,900
Conversion percentage																													50.00%
Convertible Notes Payable Three of the Notes [Member] | Unrelated Third Parties [Member]
Repayments of convertible debt																									$ 13,500
Convertible Notes Payable Six of the Notes [Member] | Unrelated Third Parties [Member]
Debt conversion, converted instrument, shares issued | shares																									800,000,000
Repayments of convertible debt																									$ 87,100
Convertible Loans One [Member]
Debt instrument, unamortized discount net issuance costs																	0								22,344																				22,344	0						0	22,344
Convertible notes payable																	$ 1,832,439								5,814,047																				5,814,047	1,832,439						1,832,439	5,814,047
Convertible Notes Payable One [Member] | Convertible Debtentures [Member]
Debt instrument, interest rate																																						8.00%
Debt principal amount																									220,000																				220,000								220,000
Convertible notes payable																									1,412,175													$ 200,000							1,412,175								1,412,175
Debt instrument convertible debt percentage																																						24.00%
Debt maturity date																																						Feb. 28, 2019
Conversion percentage																																						60.00%
Trading days | d																																						25
Derivative loss																																						$ 1,646,242
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate																																					8.00%
Debt principal amount																									66,000																				66,000								66,000
Convertible notes payable																									417,576												$ 60,000								417,576								417,576
Debt instrument convertible debt percentage																																					24.00%
Conversion percentage																																					60.00%
Note Holder [Member] | Convertible Debtentures [Member]
Debt conversion, converted instrument, shares issued | shares																	107,133,333
Debt principal amount																	$ 22,000																													22,000						22,000
Debt instrument accrued interest																	10,140
Convertible Notes Payable Two [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate																																			8.00%
Debt principal amount																									60,000																				60,000								60,000
Convertible notes payable																									369,372										$ 60,000										369,372								369,372
Debt instrument convertible debt percentage																																			24.00%
Debt maturity date																																			May 31, 2019
Conversion percentage																																			60.00%
Trading days | d																																			25
Derivative loss																																			$ 59,257
Convertible Notes Payable Three [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate																																8.00%
Debt principal amount																									31,500																				31,500								31,500
Convertible notes payable																									183,565							$ 31,500													183,565								183,565
Debt instrument convertible debt percentage																																24.00%
Debt maturity date																																Aug. 31, 2019
Conversion percentage																																60.00%
Trading days | d																																25
Derivative loss																																$ 23,794
Convertible Notes Payable [Member]
Convertible notes payable																		467,319
Non-payment penalty charges																		$ 467,319
Convertible Notes Payable Four [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member]
Debt instrument, interest rate																																	8.00%
Convertible notes payable																	124,483								180,176								$ 50,000												180,176	124,483						124,483	180,176
Debt instrument convertible debt percentage																																	24.00%
Debt maturity date																																	Jul. 31, 2019
Conversion percentage																																	55.00%
Trading days | d																																	15
Derivative loss																																	$ 46,734
Convertible Notes Payable Five [Member] | Convertible Debtentures [Member] | Non Related Party Twenty Two[Member]
Debt instrument, interest rate																																8.00%
Convertible notes payable																	48,933								70,635							$ 20,000													70,635	48,933						48,933	70,635
Debt instrument convertible debt percentage																																24.00%
Debt maturity date																																Aug. 31, 2019
Conversion percentage																																55.00%
Trading days | d																																15
Derivative loss																																$ 17,829
Convertible Notes Payable [Member]
Convertible notes payable																	129,832								253,000																				253,000	129,832						129,832	253,000
Convertible Notes Payable [Member] | Six Tranches [Member]
Convertible notes payable																	398,354																													398,354						398,354
Convertible Promissory Note [Member]
Debt discount																									22,344																				22,344								22,344
Debt instrument, unamortized discount net issuance costs																									40,000																				$ 40,000								40,000
Debt conversion, converted instrument, shares issued | shares																																												500,000,000	750,000,000
Repayments of notes payable																												27,000
Debt principal amount																	123,354								272,374																				$ 272,374	123,354						123,354	272,374
Interest payable																												11,412
Convertible notes payable																	246,708								240,000																				240,000	246,708						246,708	240,000
Amortization of debt discount																									$ 4,688																										$ 0	22,344
Stock issued during period, restricted stock | shares																									16,000,000
Debt conversion principle amount																																												$ 175,000	100,000
Number of shares issued for conversion of debt																																												$ 425,000	275,000
Derivative loss																									$ 240,000			$ 610,210																	240,000								240,000
Debt instrument conversion terms																									The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion.			The note is due two years from the execution and funding of the note per tranche. The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion.
Convertible Promissory Note [Member] | Maximum [Member]
Debt instrument convertible price per share | $ / shares																												$ 0.0005
Debt principal amount																												$ 1,000,000
Convertible Promissory Note [Member] | Unrelated Third Party [Member]
Debt discount																	0								$ 22,344																				22,344	0						0	22,344
Convertible notes payable																	576,000								$ 800,000																				$ 800,000	576,000						576,000	$ 800,000
Convertible Promissory Note [Member] | Note Agreement [Member]
Convertible notes payable																	$ 83,917																													$ 83,917						$ 83,917
Debt maturity date																																																				Apr. 30, 2023

Debts - Schedule of Future Mini

Debts - Schedule of Future Minimum Principal Payment (Details)	Dec. 31, 2020USD ($)
Debt Disclosure [Abstract]
2021	$ 10,725
2022	56,290
2023	3,283
2024	3,408
2025	3,538
Thereafter	137,551
Total	$ 214,795

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Jun. 24, 2021	Jun. 02, 2021	Apr. 26, 2021	Mar. 03, 2021	Feb. 25, 2021	Oct. 05, 2020	Sep. 21, 2020	Feb. 18, 2020	Jan. 21, 2020	Jun. 06, 2019	May 31, 2019	May 06, 2019	Oct. 30, 2017	Nov. 30, 2020	Oct. 31, 2020	Sep. 30, 2020	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	May 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Aug. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Mar. 07, 2018	Dec. 31, 2016
Common stock, shares authorized																						8,000,000,000									8,000,000,000	8,000,000,000	2,000,000,000
Preferred stock, shares authorized													20,000,000									20,000,000									20,000,000	20,000,000
Available for distribution, cash per share													$ 0.133
Number of shares issued for conversion of debt, shares						107,817,770	107,133,333	250,000,000	250,000,000	250,000,000	250,000,000	250,000,000
Number of shares issued for conversion of debt						$ 64,691	$ 171,413	$ 275,000	$ 150,000	$ 100,000	$ 100,000	$ 75,000
Notes payable																						$ 8,260,866									$ 4,895,193	$ 8,260,866
Debt instrument accrued interest																															30,850	66,460
Repayment of related party																															$ 22,150	$ 134,015
Common stock per share value																						$ 0.001									$ 0.001	$ 0.001
Stock issued during the period for services																																$ 30,000
Note Payable Two [Member]
Notes payable																						$ 1,385,163									$ 1,346,057	1,385,163
Debt instrument, unamortized discount net issuance costs																						$ 8,921									1,500	8,921
Restricted Stock [Member] | Consultant [Member]
Stock issued during the period for services, shares																						15,000,000				120,000,000
Stock issued during the period for services																						$ 6,000				$ 24,000
Restricted Stock [Member] | Settlement of Accrued Liabilities and Debt [Member]
Stock issuance during period, shares																											81,000,000
Debt, default penalty																																		$ 110,000
Stock issuance during period, value																											$ 32,400
Restricted Stock [Member] | Debt Modification and Penalty [Member] | Three Note Holders [Member]
Stock issuance during period, shares																								3,500,000	3,500,000
Stock issuance during period, value																								$ 1,050	$ 1,050
Restricted Stock [Member] | Debt Modification and Penalty [Member] | Five Note Holders [Member]
Stock issuance during period, shares																													18,500,000
Stock issuance during period, value																													$ 6,650
Restricted Stock [Member] | Consultant Agreement [Member]
Stock issued during the period for services, shares																												100,000,000
Common stock per share value																												$ 0.0012
Note Holder [Member]
Number of shares issued for conversion of debt, shares	2,500,000	5,700,000	27,070,000	67,380,000	137,700,000										107,817,770
Number of shares issued for conversion of debt	$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930
Debt instrument, face amount															$ 22,000
Debt instrument accrued interest															$ 10,345
Non Related Party Ten [Member]
Notes payable																															84,000
Debt discount																															14,000
Non Related Party Ten [Member] | Note Payable Two [Member]
Notes payable																			$ 50,000			$ 120,000										120,000
Debt instrument, unamortized discount net issuance costs																			120,000
Debt discount																			$ 20,000
Number of shares issued for settlement of debt																			125,000,000
Related Party Note [Member]
Number of shares issued for conversion of debt, shares																		5,000,000
Fair value of convertible debt																		$ 3,000
Repayment of related party																		$ 14,400
Three note holder [Member] | Restricted Stock [Member]
Equity compensation charge																																50,000
Four note holder [Member] | Restricted Stock [Member]
Equity compensation charge																															$ 8,500	$ 21,500
Common Stock [Member]
Stock issued during the period for services, shares																																135,000,000
Stock issued during the period for services																																$ 135,000
Notes Payable [Member] | Common Stock [Member]
Number of shares issued for debt																							20,000,000	16,000,000	6,000,001
Number of shares issued for debt, shares																							$ 5,895	$ 4,688	$ 1,800
Notes Payable [Member]
Number of shares issued for conversion of debt, shares																				500,000,000				750,000,000	750,000,000					107,133,333
Number of shares issued for conversion of debt																								$ 275,000	$ 275,000
Debt instrument, face amount											$ 100,000									$ 175,000				$ 100,000	$ 100,000					$ 22,000
Notes payable																														511,319
Debt instrument accrued interest																														$ 10,140
Note Holder [Member]
Number of shares issued for conversion of debt, shares																					75,000,000
Repayment of related party																					$ 45,000
Note Holder [Member] | Restricted Stock [Member]
Number of restricted common shares, shares															1,500,000	10,000,000	1,000,000
Number of restricted common shares															$ 900	$ 6,000	$ 700
Repayment of related party															$ 84,000	$ 333,543	$ 22,000
Note Holder [Member] | Third Party [Member] | Restricted Stock [Member]
Debt instrument, face amount																											20,000
Notes payable																											$ 75,900
Number of restricted common shares, shares														100,000,000
Number of restricted common shares														$ 20,000
Fair value of convertible debt														$ 140,000
Six Convertible Promissory Notes [Member] | Restricted Stock [Member] | Settlement of Accrued Liabilities and Debt [Member]
Stock issuance during period, shares																						800,000,000
Number of shares issued for conversion of debt																						$ 29,381
Debt instrument, face amount																						87,100										87,100
Notes payable																						19,984										19,984
Stock issuance during period, value																						454,000
Debt, outstanding fee																						39,000										$ 39,000
Other expense, debt																						$ 244,632
Settlement and Restatement of Promissory Notes[Member]
Stock issuance during period, shares																			36,000,000
Settlement and Restatement of Promissory Notes[Member] | Adjustments Decrease in Net Loss [Member]
Stock issuance during period, shares																			10,000,000
Stock issuance during period, value																			$ 119,700
Series A Preferred Stock [Member]
Stock issuance during period, shares													3,000,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($)	Oct. 05, 2020	Sep. 21, 2020	Feb. 18, 2020	Jan. 21, 2020	Jun. 06, 2019	May 31, 2019	May 06, 2019
Equity [Abstract]
Number of shares converted	107,817,770	107,133,333	250,000,000	250,000,000	250,000,000	250,000,000	250,000,000
Fair value of debt converted	$ 64,691	$ 171,413	$ 275,000	$ 150,000	$ 100,000	$ 100,000	$ 75,000

Stock Warrants (Details Narrati

Stock Warrants (Details Narrative) - USD ($)	Oct. 31, 2020	Oct. 31, 2020	Aug. 31, 2020	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2017	Apr. 04, 2016	Mar. 03, 2016	Apr. 30, 2014
Notes Payable				$ 8,260,866		$ 4,895,193	$ 8,260,866
Number of warrants to purchase common stock												100,000
Warrants, exercise price per share												$ 0.025
Fair value of warrants		$ 16,500	$ 20,848	7,370	$ 8,147			$ 0
Warrants, expiration date												Apr. 9, 2019
Convertible Notes Payable [Member]
Fair value of warrants		8,633
Debt instrument, original discount					5,000
Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Notes Payable						555,600
Debt instrument, face amount	$ 16,500	16,500	38,500
Debt instrument, original discount	1,650	$ 1,650	$ 7,550
Debt instrument, due date		2021-04	2021-02
Two Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount	57,500	$ 57,500
Debt instrument, original discount	$ 7,500	$ 7,500
Three Convertible Notes Payable [Member]
Notes Payable					$ 70,000
Warrants, exercise price per share					$ 0.001
One Convertible Notes Payable [Member]
Notes Payable				$ 22,000			22,000
Three Year Warrant [Member]
Notes Payable									$ 80,000
Warrants, term									3 years	3 years
Number of warrants to purchase common stock									6,000,000	4,000,000
Warrants, exercise price per share									$ 0.005	$ 0.05
Fair value of warrants						0	539	$ 0
Warrants, expiration date									Mar. 30, 2020	Apr. 4, 2019
Five Year Warrant [Member]
Warrants, term											5 years
Number of warrants to purchase common stock											2,500,000
Warrants, exercise price per share											$ 0.03
Fair value of warrants						$ 9	$ 872
Warrants, expiration date											Mar. 3, 2021
Warrants [Member]
Number of warrants to purchase common stock						123,900
Warrants, exercise price per share	$ 0.002	$ 0.002
Debt instrument, original discount	$ 7,500	$ 7,500
Number of warrants, granted	71,875,000
Number of warrants	$ 50,000	$ 50,000
Warrants, intrinsic value						$ 25,680
Stock price						$ 0.0012
Warrants [Member] | Convertible Notes Payable [Member]
Number of warrants to purchase common stock	36,300,000	36,300,000	92,100,000	44,000,000	110,000,000		44,000,000
Warrants, exercise price per share	$ 0.001	$ 0.001
Fair value of warrants		$ 16,500	$ 38,500	$ 7,370	$ 8,147
Warrants, expiration date	Oct. 31, 2022	Oct. 31, 2022	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2019		Aug. 31, 2020
Debt instrument, original discount	$ 29,481	$ 29,481
Warrants [Member] | Convertible Note [Member]
Warrants, exercise price per share						$ 0.001
Money Warrants [Member]
Number of warrants						$ 128,400,000

Stock Warrants - Schedule of Wa

Stock Warrants - Schedule of Warrants Issued (Details) - USD ($)	1 Months Ended				12 Months Ended
	Oct. 31, 2020	Aug. 31, 2020	Dec. 31, 2019	Feb. 28, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Number of Warrants	36,300,000	92,100,000	44,000,000	110,000,000
Fair Value of Warrants	$ 16,500	$ 20,848	$ 7,370	$ 8,147	$ 0
Month of Expiration	October, 2022	August, 2021	August, 2020	August, 2019

Stock Warrants - Summary of War

Stock Warrants - Summary of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Weighted Average Exercise Price, Warrants, Beginning	$ 0.0028
Weighted Average Exercise Price, Warrants, Ending	$ 0.0017	$ 0.0028
Warrants [Member]
Number of warrants outstanding, Beginning	52,500,000	12,600,000
Number of warrants, Exercised
Number of warrants, Issued	200,275,000	154,000,000
Number of warrants, Expired	(50,000,000)	(114,100,000)
Number of warrants outstanding, Ending	202,775,000	52,500,000
Weighted Average Exercise Price, Warrants, Beginning	$ 0.0028	$ 0.026
Weighted Average Exercise Price, Warrants, Exercised
Weighted Average Exercise Price, Warrants, Issued	0.0014	0.001
Weighted Average Exercise Price, Warrants, Expired	0.0015	0.0027
Weighted Average Exercise Price, Warrants, Ending	$ 0.0017	$ 0.0028

Stock Warrants - Summary of Fix

Stock Warrants - Summary of Fixed Price Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Apr. 30, 2014
Exercise Price			$ 0.025
Weighted Average Number Outstanding	51,086,612	10,187,671
Weighted Average Contractual Life	11 months 4 days	7 months 13 days
Weighted Average Exercise Price	$ 0.0017	$ 0.0028
Minimum [Member]
Exercise Price	0.001	0.001
Maximum [Member]
Exercise Price	$ 0.03	$ 0.03

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Valuation allowance, increase (decrease) amount	$ 340,617	$ 356,603
Operating loss carry forward, net	38,400,000		$ 3,000,000
Expired Between 2024 and 2037 [Member]
Operating loss carry forward, net	$ 35,400,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal tax rate	21.00%	21.00%
Add: State taxes	5.50%	5.50%
Permanent difference	(1.15%)	(1.15%)
Valuation allowance	(25.35%)	(25.35%)
Tax rate

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Computed "expected" tax expense (benefit) - Federal	$ (161,529)	$ (1,384,203)
Computed "expected" tax expense (benefit) - State	(33,421)	(286,398)
Permanent differences	(145,667)	1,313,998
Change in valuation allowance	340,617	356,603
Provision for income taxes

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Reserve for prepaid inventory	$ 23,573	$ 18,174
Accrued salary	362,356	316,659
Reserve(recovery) for receivables from officer	(25,979)	14,954
Net operating loss carryforwards	9,729,342	9,398,889
Valuation allowance	(10,089,292)	(9,748,676)
Net deferred income tax asset

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued consulting fees	$ 166,900	$ 161,550
Accrued settlement expenses	35,000	35,000
Accrued payroll taxes	215,581	167,906
Accrued interest	351,830	231,186
Accrued others	11,121	16,905
Total	$ 780,432	$ 612,547

Prepaid Expenses (Details Narra

Prepaid Expenses (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Future reserve for purchases	$ 21,303	$ 23,948
Total valuation allowance for prepaid	$ 246,162	$ 224,859

Prepaid Expenses - Schedule of

Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Supplier advances for future purchases	$ 246,162	$ 224,859
Reserve for supplier advances	(246,162)	(224,859)
Net supplier advances
Prepaid professional fees	10,000	8,650
Deferred stock compensation		8,500
Total	$ 10,000	$ 17,150

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 15, 2019	Aug. 01, 2017	Apr. 12, 2017	Aug. 26, 2016	Feb. 28, 2016	Oct. 31, 2015	Jul. 31, 2015	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2016
Operating lease term					3 years
Operating lease due					$ 3,200
Lease expiration date					Feb. 28, 2019
Lease, description					The lease on a month-to-month basis until May 2020
Common stock shares issued									6,955,197,214	5,876,746,111	1,000,000
Note issued									$ 87,500	$ 486,400
Shares issued, price per share									$ 0.18	$ 0.18
Accrued liabilities for commissions, expense and taxes									$ 142,500
Equity compensation charges											$ 31,750
Accrued expenses									$ 19,150	$ 19,150
Share based compensation, shares not yet issued									1,500,000	1,500,000
Long-term debt									$ 214,795
Loss contingency, allegations									The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company's stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief.
Consulting Services Agreement [Member] | Restricted Stock [Member]
Consulting service term							5 years
Common stock shares issued							500,000
Debt instrument, interest rate							8.00%
Note issued							$ 50,000
Consultant Agreement [Member]
Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted						2,500,000
Consultant Agreement [Member] | Common Stock [Member]
Debt instrument periodic payment						$ 3,000
Recepto Pharm Leases [Member]
Operating lease due		$ 6,900
Lease, description		ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year.
Paul Reid et al [Member]
Loss contingency, damages sought, value				$ 315,000
Get Credit Healthy, Inc. and Rik Deitsch,[Member]
Loss contingency, damages sought, value			$ 100,000
Payments for legal settlements	$ 104,000							$ 88,500
CSA 8411, LLC [Member]
Long-term debt									$ 91,156
Long-term debt, accrued interest									$ 40,917

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Lease Cost and Balance Sheet Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 89,021	$ 89,021
Short-term lease cost	18,698	45,026
Total lease cost	107,719	134,047
Operating ROU Assets	144,010	207,530
Operating lease obligations, current portion	82,873	73,278
Operating lease obligations, non-current portion	60,447	143,322
Total operating lease obligations	$ 143,320	$ 216,600
Weighted average remaining lease term (in years) - operating leases	1 year 11 months 1 day	2 years 8 months 2 days
Weighted average discount rate-operating leases	8.00%	8.00%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 98,780	$ 79,950

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Future Minimum Payments Under Lease Agreements (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Feb. 28, 2016
Total future lease payments			$ 3,200
Total	$ 143,320	$ 216,600
Lease Agreements [Member]
2021	91,379
2022	62,274
Total future lease payments	153,653
Less imputed interest	10,333
Total	$ 143,320

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 31, 2021	Aug. 28, 2021	Aug. 05, 2021	May 20, 2021	Mar. 10, 2021	Jun. 30, 2021	Apr. 30, 2021	Mar. 31, 2021	Feb. 28, 2021	Jan. 31, 2021	Oct. 31, 2020	Jul. 31, 2020	Dec. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2021	Aug. 31, 2021	Jul. 31, 2021	Feb. 28, 2019	Dec. 31, 2018
Debt instrument accrued interest																		$ 30,850	$ 66,460
Loss on settlement of debt																		1,587,293	92,621
Repayments of convertible debt																		$ 5,782	$ 13,500
Restatement of Promissory Notes [Member]
Debt instrument, face amount												$ 166,926
Debt instrument, interest rate,												2.00%
Restatement of Promissory Notes [Member] | Restated [Member]
Debt instrument, face amount												$ 148,225
Debt instrument accrued interest												18,701
Restatement of Promissory Notes [Member]
Debt instrument, face amount												$ 166,926
Debt instrument, due date												2021-01
Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount																								$ 12,000
Consultant [Member] | Restricted Stock [Member]
Stock issued during the period for services, shares													15,000,000	120,000,000
Note Holder [Member]
Debt instrument, face amount											$ 22,000
Debt instrument accrued interest											10,345
Subsequent Event [Member] | Restatement of Promissory Notes [Member]
Debt instrument accrued interest									$ 23,258
Number of shares issued									29,072,500
Number of shares issued, value									$ 343,056
Other income									319,798
Restated debt balance									183,619
Subsequent Event [Member] | Restatement of Promissory Notes [Member] | Restated [Member]
Debt instrument, face amount									$ 166,926
Debt instrument, due date									2021-08
Debt instrument, original discount									$ 16,693
Subsequent Event [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount							$ 8,500
Debt instrument fair value							$ 15,200
Number of shares issued							2,000,000
Number of shares issued, value							$ 4,000
Repayment of debt							4,500
Loss on settlement of debt							$ 11,200
Subsequent Event [Member] | Unrelated Third Parties [Member] | Common Stock Issued for Default Payments [Member]
Debt instrument, face amount					$ 26,950
Debt instrument, original discount					$ 2,450
Debt conversion price					$ 0.01
Debt instrument, expiration or maturity date					Mar. 10, 2022
Subsequent Event [Member] | Unrelated Third Parties [Member] | Convertible Promissory Note [Member]
Debt instrument, face amount			$ 55,000	$ 145,200
Debt instrument, original discount			$ 5,000	$ 13,200
Debt conversion price			$ 0.01	$ 0.01
Debt instrument, expiration or maturity date			Aug. 5, 2022	May 20, 2022
Subsequent Event [Member] | Consultant [Member] | Common Stock Issued for Consulting Servicetock Issued for Default Payments [Member] | Restricted Stock [Member]
Stock issued during period, restricted stock						5,000,000
Number of shares issued						5,000,000
Stock issued during the period for services, shares						30,000,000
Subsequent Event [Member] | Note Holder [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount																				$ 11,000
Number of shares issued								11,000,000
Number of shares issued, value								$ 104,500
Repayment of debt								6,000
Loss on settlement of debt								98,500
Subsequent Event [Member] | Note Holder [Member] | Common Stock Issued for Default Payments [Member] | Restricted Stock [Member]
Stock issued during period, restricted stock										25,000,000
Stock issued during period, restricted stock value										$ 107,500
Repayments of convertible debt										$ 166,926
Repayments of Debt in Cash [Member] | Subsequent Event [Member] | Note Holder [Member] | Settlement of Convertible Promissory Notes [Member]
Repayment of debt								$ 5,000
Convertible Notes Payable [Member]
Debt instrument, original discount																							$ 5,000
Debt instrument accrued interest											166,168
Convertible Notes Payable [Member] | Restatement of Promissory Notes [Member]
Repayments of convertible debt															$ 75,900
Convertible Notes Payable [Member] | Convertible Promissory Note [Member]
Debt instrument, original discount											$ 1,650
Convertible Notes Payable [Member] | Minimum [Member]
Debt conversion price													$ 0.00010					$ 0.00050	$ 0.00010
Convertible Notes Payable [Member] | Maximum [Member]
Debt conversion price													$ 0.000293					$ 0.00064	$ 0.000293
Convertible Notes Payable [Member] | Subsequent Event [Member] | Minimum [Member]
Debt conversion price								$ 0.0003												$ 0.0008
Convertible Notes Payable [Member] | Subsequent Event [Member] | Maximum [Member]
Debt conversion price								$ 0.002												$ 0.002
Convertible Notes Payable [Member] | Subsequent Event [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount								$ 717,667												$ 864,225	$ 415,150	$ 415,150
Debt instrument, original discount								$ 93,609												112,725	$ 54,150	$ 54,150
Debt conversion price																					$ 0.002	$ 0.002
Convertible Notes Payable [Member] | Subsequent Event [Member] | Note Holder [Member]
Debt instrument, face amount																				83,917
Debt instrument, due date																	2023-06
Stock issued during period, restricted stock																	240,350,000
Stock issued during period, restricted stock value																	$ 120,175
Debt instrument fair value																				$ 2,344,399
Convertible Notes Payable [Member] | Note Agreement [Member]
Debt instrument, face amount																							$ 1,000,000
Proceeds from loan																		$ 392,573
Convertible Notes Payable [Member] | Note Agreement [Member] | Subsequent Event [Member]
Proceeds from loan	$ 80,738	$ 86,520
Stock issued during period, restricted stock																240,350,000
Stock issued during period, restricted stock value																$ 120,175
Debt instrument fair value	$ 2,344,399															$ 2,344,399

Subsequent Events - Schedule of

Subsequent Events - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($)	Jun. 24, 2021	Jun. 02, 2021	Apr. 26, 2021	Mar. 03, 2021	Feb. 25, 2021	Oct. 05, 2020	Sep. 21, 2020	Feb. 18, 2020	Jan. 21, 2020	Jun. 06, 2019	May 31, 2019	May 06, 2019	Oct. 31, 2020
Number of shares converted						107,817,770	107,133,333	250,000,000	250,000,000	250,000,000	250,000,000	250,000,000
Fair value of debt converted						$ 64,691	$ 171,413	$ 275,000	$ 150,000	$ 100,000	$ 100,000	$ 75,000
Note Holder [Member]
Number of shares converted	2,500,000	5,700,000	27,070,000	67,380,000	137,700,000								107,817,770
Fair value of debt converted	$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930